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Abstract
Members of the highly conserved pleiotropic CK1 family of serine/threonine-specific kinases are 
tightly regulated in the cell and play crucial regulatory roles in multiple cellular processes from 
protozoa to human. Since their dysregulation as well as mutations within their coding regions 
contribute to the development of various different pathologies, including cancer and 
neurodegenerative diseases, they have become interesting new drug targets within the last decade. 
However, to develop optimized CK1 isoform-specific therapeutics in personalized therapy 
concepts, a detailed knowledge of the regulation and functions of the different CK1 isoforms, their 
various splice variants and orthologs is mandatory. In this review we will focus on the stress-
induced CK1 isoform delta (CK1δ), thereby addressing its regulation, physiological functions, the 
consequences of its deregulation for the development and progression of diseases, and its potential 
as therapeutic drug target.
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1. Introduction
CK1δ, a member of the CK1 (formerly named casein kinase 1) family, has been first isolated 
by Graves and colleagues in the early 1990s. The human gene encoding CK1δ (CSNK1D) is 
located on the long arm of the chromosome 17 (17q25.3) (Graves et al., 1993). In the last 
decades the roles of CK1δ have been characterized more and more, both in physiological 
and in pathologic conditions. In fact, dysregulation of the expression and activity of CK1δ 
has been observed in different types of cancers, as well as in different neurological 
disorders, among them Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and 
Amyotrophic Lateral Sclerosis (ALS). CK1 isoforms δ and ε exhibit high identity within 
their kinase domains but no differences of their functional roles were detected in several 
early studies. Even though it still remains challenging to assign distinct functions to one of 
the human CK1 isoforms (α, γ1–3, δ, ε), new studies are now focusing on this issue. 
Considering the fact that even CK1δ transcription variants (TVs) exhibit different functions, 
there is a need to clearly state, which isoform or even TV has been used to receive detailed 
information and to increase reproducibility of the data by other researchers (Fustin et al., 
2018; Narasimamurthy et al., 2018). From this point of view there is a high demand to 
develop highly specific, isoform- or even TV-specific therapeutics which could be of use in 
personalized therapy concepts for the treatment of neurodegenerative diseases and cancer. 
The present review will focus on CK1δ, its regulation, functions, its relevance in human 
diseases, and as a target for drug development.
2. Genetic coding of CK1δ
Historically, the initial gene sequence of CK1δ was isolated by Graves et al. in form of 
cDNA from the testicles of rats in the year 1993. The gene construct was sequenced and 
characterized as a 1284 nucleotide sequence transcribing into a 49 kDa protein consisting of 
428 amino acids (aa) (Graves et al., 1993). This sequence was followed by the human gene 
construct with 1245 nucleotides describing a protein containing 415 aa (Kusuda et al., 
1996). In the following years CK1δ was discovered and described in yeasts, various animals, 
plants, and even parasites (Barik et al., 1997; Donald et al., 2005; Allocco et al., 2006; 
Urbaniak, 2009; Rachidi et al., 2014; Dorin-Semblat et al., 2015) (Table 1).
Although there are various variants of CK1δ in different organisms, three different TVs of 
CK1δ are present in humans, in rat (Rattus norvegicus) and in mice (Mus musculus).
All three different CK1δ TVs expressed in human, rat, and mouse do not differ in their 
amino acid sequences until position 381. After position 399 three distinct sequences for the 
respective TVs can clearly be distinguished as illustrated in Fig. 1.
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The Clustal Omega algorithm (Madeira et al., 2019) identifies three distinct sequences that 
are shared between the three different organisms: the shortest sequence containing 409 aa 
(TV2 in humans and rat as well as CRAc in mouse), followed by a sequence consisting of 
415 aa (TV1 in humans and rats/CRAa in the mouse), and a sequence containing 428 aa for 
the mouse (CRAb) and the rat (TV3) homolog as well as a human TV3 sequence, which is 
missing one aa at the second to last position, resulting in a length of 427 aa.
In addition to the shown sequences of human, rat, and mouse, CK1δ sequences in most 
eukaryotic organisms are homologous. The phylogenetic tree displayed in Supplementary 
Fig. 1 resembles the degree of evolutionary relationship between various sequences of 
CK1δ.
2.1. Analysis of transcription variants of CK1δ
Various TVs of the gene CSNK1D have been described in the “Mammalian Gene 
Collection”. Two different TVs of CK1δ were postulated during the early analysis of human 
and murine genes in 2002 (Strausberg et al., 2002). Since then TV1 (accession number: 
AAH03558.1, GI: 13097702) and TV2 (accession number: AAH15775.1, GI: 16041786) 
have been well described in literature. Recently, it could be clearly shown that both variants 
exhibit opposite functions in the circadian rhythm (Fustin et al., 2018). Both sequences are 
highly homologous and are alike for the first 399 aa, but differ at the following 16 aa for 
TV1 and ten aa for TV2, respectively. They do share the first eight exons. The variance 
occurs due to the fact that TV1 is finished by exon 10, while TV2 uses exon 9. TV2 also 
includes exon 10, but after the first ten amino acids of exon 9 a stop codon halts the 
translation and prevents the translation of exon 10 (Fig. 2).
Additionally, a third human TV (TV3, accession number: NP_001350678.1, GI: 
1393428169), which is very similar to the original CK1δ rat sequence published by Graves 
and colleagues (Graves et al., 1993), can be found on chromosome 17 (accession number: 
NG_012828.2, GI: 1428083528). TV3 uses exon 11 instead of 9 and 10. Exon 11 is located 
downstream of exon 10 and is overlapping with the gene Slc16a3. However, exon 11 is 
located in a non-coding area. The use of the different exons resulting in the three 
transcription variants is depicted in Fig. 2.
The inclusion of exon 11 used for TV3 increases the initially postulated length of the CK1δ 
gene (CSNK1D) from 29.3 kb to approximately 35 kb, which means the length is similar to 
the rat CSNK1D gene with 34.6 kb.
All three transcription variants were identified in 2014 by the data bank analysis approach 
by Ezkurdia et al. (2014). Even though the study combined the detection of cellular protein 
expression by peptide mass spectrometry with the protein-coding potential of the genome, at 
that time no specific evidence was provided indicating that all three TVs are actually 
translated. Furthermore, TV3 is listed as “unreviewed” entry in the UniProtKB data base 
(H7BYT1_HUMAN).
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2.2. Polyadenylation patterns of transcription variants
Analysis of polyadenylation sites using the tool RegRNA 2.0 for identification of functional 
RNA motifs (Chang et al., 2013) revealed that TV1 and TV2 share the same polyadenylation 
pattern downstream of the stop codon on exon 10, starting at position 1246. The identified 
motif is 32 nucleotides long (AGUAGAGUCUGCGCUGUGACCUUCUGUUGGGC).
Since exon 10 is not present in TV3, a 32 nucleotides long sequence 
(AGUGGCUUGUUCCACCUCAGCUCCCAUCUAAC) located downstream of the stop 
codon on exon 11, at the starting nucleotide 320, is used. The various motifs result in 
different minimum free energy values (−28.70 kcal/mol for TV1 and TV2, and −16.03 
kcal/mol for TV3). The predicted RNA folding structures of the respective motifs with 
flanking regions are depicted in Fig. 3.
3. CK1δ structure and domains
As an own family within the superfamily of serine/threonine-specific kinases all CK1 
members are composed by two lobes, basically building all eukaryotic protein kinases 
(ePKs): the N-terminal lobe (N-lobe) mainly consists of β-sheet strands while the larger C-
terminal lobe (C-lobe) is mainly composed by α-helices and loop structures (Fig. 4). Apart 
from five twisted antiparallel β-strands (β1-β5), the N-lobe also contains a prominent α-
helix (αA) crucial for conformational regulation of kinase activity. Within the C-lobe, loop 
L-78 has previously been attributed to the modulation of CK1 inhibitor selectivity (Peifer et 
al., 2009) and binding of a tungstate derivative (as a phosphate analog) identified a 
recognition motif (W1) for the binding of phosphorylated substrates. Major sites involved in 
mediating substrate recognition are Arg-178, Gly-215, and Lys-224. Positively charged side 
chains of Arg-178 and Lys-224, but also Lys-217, Lys-221, and Arg-222 enable the 
formation of ionic interactions with acidic or phospho-primed substrates. This also applies 
for binding of the C-terminal domain to the substrate binding region for the purpose of 
autoregulatory function (Longenecker et al., 1996). Upon substrate binding the phospho-
acceptor group of the targeted Ser/Thr residue is directed to the γ-phosphate of 
simultaneously bound ATP, located in close proximity within H-bonding range. Also loop L-
EF is putatively involved in substrate recognition and binding, although some residues of 
this loop could not be modelled in several studies due to poor electron density. Therefore, 
this loop has been found to be partially disordered in previously performed analyses of 
CK1δ structure (Longenecker et al., 1996; Zeringo et al., 2013). Additionally, residues 
Asn-172 and Thr-176 seem to be crucial for substrate binding and/or kinetic activity of 
CK1δ. The amino acid exchange N172D was identified by analyzing the CK1δ sequence of 
the simian virus 40 (SV40)-minimally transformed rat fibroblast cell line Rev2. The 
substitution of asparagine by aspartic acid is supposed to significantly alter the electrostatic 
potential of the protein surface from neutral to acidic, resulting in impaired kinase activity 
(Hirner et al., 2012). Within the same region of this substrate binding area also residue 
Thr-176 can be found. A point mutation leading to the amino acid replacement T176I was 
originally identified in Hrr25, the CK1δ ortholog in Saccharomyces cerevisiae (Murakami et 
al., 1999). This amino acid exchange resulted in a loss-of-function phenotype with only little 
residual kinase activity and has been used in various studies in order to create mutants of 
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CK1δ with insufficient kinase activity (Murakami et al., 1999; Milne et al., 2001; 
Mehlgarten and Schaffrath, 2003).
A catalytic cleft for binding of substrates and ATP is formed between the N- and C-terminal 
lobe of CK1, which are connected via a hinge region (Xu et al., 1995, Longenecker et al., 
1996). The ATP active site is formed by two binding regions: a deep hydrophobic pocket 
(HPI, also known as selectivity pocket) and a second spacious hydrophobic region (HRII). 
Furthermore, sugar and phosphate binding domains can be found in the ATP active site 
(Peifer et al., 2009). The glycine-rich P-loop contains the motif Gly-X-Gly-X-X-Gly and 
bridges strands β1 and β2 (L-12) by forming a β-strand-turn-β-strand motif. This P-loop 
builds the top cover of the ATP binding site, usually holds the non-transferable phosphate of 
ATP in place, and is assumed to be more flexible as long as no ATP is present in the ATP 
binding pocket (Hantschel and Superti-Furga, 2004; Zeringo et al., 2013).
Residues directly involved in forming interactions in the ATP binding site have been 
analyzed by Singh and Gupta (Singh and Gupta, 2015). In this study the incomplete 
structure of CK1δ has initially been completed by homology modeling (starting from the 
structure of CK1α). By using FTsiteserver active site residues Gly-18, Ser-19, Phe-20, 
Asp-22, Lys-38, Leu-39, Glu-40, Gln-48, Leu-49, and Glu-52 were predicted for the newly 
created CK1δ structure, termed dCK1-M (Singh and Gupta, 2015). Lysine residue 38 is also 
conserved in isoforms CK1α (Lys-46) and CK1ε (Lys-38) and is crucial for ATP binding 
and kinase activity, since substitution of this residue, usually by arginine or methionine, 
completely abolishes kinase activity creating a kinase-dead CK1δ mutant (Rivers et al., 
1998; Budd et al., 2000; Milne et al., 2001; Zeringo et al., 2013; Singh and Gupta, 2015). 
Furthermore, the so called catalytic loop (L-67) with the sequence Asp-Val-Lys-Pro-Asp-
Asn (amino acids 128–133) is also essential for ATP binding. Residue Asp-128 can even be 
considered as catalytic base (Xu et al., 1995; Zeringo et al., 2013) (Fig. 5).
Kinase activity of eukaryotic protein kinases in general can be regulated by conformational 
changes affecting the so called activation loop, which in the case of CK1δ is represented by 
loop L-9D (Xu et al., 1995, Longenecker et al., 1996). Switching to an active conformation, 
the activation loop moves out of the catalytic site and the aspartate residue of the DFG motif 
(residues Asp-149, Phe-150, and Gly-151 in the case of CK1δ, located in loop L-89) shifts 
to an internal position. There, the aspartate of this highly conserved motif chelates a Mg2+ 
ion essential for ATP binding and orientation (Endicott et al., 2012). Another conserved 
eukaryotic protein kinase motif, the APE motif at the end of the activation loop, is modified 
in CK1δ and is represented by the SIN motif in helix αD (Hanks and Hunter, 1995). In 
conclusion, residues Lys-38, Lys-130 (catalytic loop residue), Asp-149 (DFG residue), and 
the P-loop act together to form interactions with the triphosphate moiety of ATP.
In addition, especially for the regulation of kinase activity, as well as for forming 
interactions with small molecule inhibitors, several residues of CK1δ encoded by exon 3 are 
essentially involved (Long et al., 2012, Richter, Ullah et al. 2015). One of them is the so 
called gatekeeper residue located directly within the ATP binding pocket. While the catalytic 
activity of the kinase usually is not affected by the size of the gatekeeper side chain, the 
affinity of small molecules, and their access to certain binding pockets (selectivity pockets) 
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beyond the gatekeeper position can be limited by gatekeeper mutations. In the case of CK1δ 
residue Met-82 (located in loop L-5B) takes the role of the gatekeeper and substitution to the 
more space-filling residue phenylalanine (M82F) actually abolished binding of a certain 
class of imidazole-based inhibitors to the selectivity pocket (HPI) in the ATP active site of 
CK1δ (Peifer et al., 2009).
In other studies however, increased affinity of benzimidazole- and benzothiazole-based 
inhibitors to the CK1δ M82F gatekeeper mutant could be observed, caused by additional π-
hydrogen bonds or π-stacking interactions between Phe-82 and the inhibitor molecules 
(Bischof et al., 2012; Garcia-Reyes et al., 2018). For another CK1δ point mutation localized 
in exon 3 resulting in S97C substitution the loss of ATP binding affinity has been detected 
by molecular dynamics simulations and docking studies, respectively (Kumar et al., 2014). 
In contrast, a CK1δ T67S mutant displayed increased kinase activity in vitro and enhanced 
oncogenic potential in cell culture experiments and in a subcutaneous tumor 
xenotransplantation model. Moreover, CK1δ T67S showed increased sensitivity toward 
CK1-specific inhibitors (Richter, Ullah et al. 2015).
Besides substrate and ATP binding regions further functional domains being involved in 
mediating protein-protein interactions are located in the CK1δ protein. Additionally, the 
kinase domain, which extends between amino acids 9 to 277, contains a kinesin homology 
domain (KHD) as well as a putative dimerization domain (DD). The DD includes residues 
from β-strands β1, β2, β3, and β7, as well as from loops L-12, L-78, helix αB, and the 
hinge region (Longenecker et al., 1998). The KHD, located within the activation-loop 
(L-9D), is supposed to mediate interactions between CK1 isoforms and components of the 
cytoskeleton (Roof et al., 1992, Xu et al., 1995, Behrend et al., 2000b). At the junction 
between L-EF and the αF-helix also a nuclear localization signal sequence (NLS) is located 
which, however, is not sufficient for nuclear localization of CK1δ (Hoekstra et al., 1991; 
Graves et al., 1993). Finally, a centrosome localization signal (CLS) domain can be found 
between residues 278 and 364 (Greer and Rubin, 2011).
Because sequences of human CK1δ TV1, 2, and 3 are fully conserved up to amino acid 399 
structural elements described so far can be found in all variants (sequence alignment of 
human CK1δ TV1, 2, and 3 can be found in Fig. 1A). Unfortunately, analysis of the three-
dimensional structure of CK1δ has only been performed with truncated proteins e.g. 
terminating at amino acids 295 or 318, respectively. This procedure is necessary in order to 
circumvent problems occurring due to C-terminal proteolysis and variable 
(auto-)phosphorylation states of the full-length protein (Longenecker et al., 1996). Although 
these proteins still contain the full kinase domain, however, no validated structural data 
regarding the C-terminal domain could be made available so far.
4. Regulation of CK1δ activity
Because CK1δ is ubiquitously expressed and its activity is essential for proper function of 
several important cellular signal transduction pathways, its expression and activity needs to 
be strictly controlled. First of all, expression of CK1δ varies between different tissues and 
cell types and is related to certain physiological and pathophysiological conditions and 
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stimuli (Lohler et al., 2009). DNA-damaging substances like the topoisomerase inhibitors 
etoposide and camptothecin, as well as γ-irradiation, resulted in tumor protein 53 (p53)-
dependent increased levels of CK1δ mRNA (Knippschild et al., 1997; Behrend et al., 
2000b). Furthermore, gastrin has been shown to induce CK1δ/ε-mediated phosphorylation 
of protein kinase D2 (PKD2) (von Blume et al., 2007), while elevated CK1-specific activity 
in general has been detected in cells upon stimulation with insulin (Cobb and Rosen, 1983) 
or viral transformation (Elias et al., 1981).
Apart from transcriptional or translational control of CK1δ protein expression, its kinase 
activity can also be regulated at protein level by sequestration to particular subcellular 
compartments, interaction with other proteins, and posttranslational modifications.
By sequestration of CK1δ to distinct subcellular compartments well defined pools of 
substrates can be made available to the kinase in order to guide its activity toward specific 
functions (Wang et al., 1992; Vancura et al., 1994; Sillibourne et al., 2002). Subcellular 
sequestration is mainly mediated by scaffolding structures containing distinct interaction 
motifs. In general, the purpose of these scaffolds is to bring interacting molecules into close 
proximity within interaction complexes in order to enable their orchestrated function in 
certain signal transduction pathways. Additionally, these scaffolds are supposed to 
allosterically control the activity of their interaction partners (Locasale et al., 2007; Good et 
al., 2011).
One of these scaffolds involved in sequestration of CK1 is A-kinase anchor protein (AKAP) 
450 (also known as AKAP350, AKAP9, or centrosomal and Golgi N-kinase anchoring 
protein [CG-NAP]). AKAP450 has been shown to specifically interact with CK1δ and ε, 
resulting in recruitment of both isoforms to the centrosome to exert centrosomespecific 
functions contributing to cell cycle regulation (Sillibourne et al., 2002; Greer and Rubin, 
2011). Moreover, interaction of AKAP450 and CK1δ has been demonstrated as one 
mechanism essential for primary ciliogenesis (Greer et al., 2014). As another example, 
previously identified as a scaffolding adaptor activating the inhibitor κB kinase (IKK), X-
linked DEAD-box RNA helicase 3 (DDX3X) has been shown to promote CK1ε-mediated 
phosphorylation of Dishevelled (Dvl) in the canonical Wingless/Int-1 (Wnt) signal 
transduction pathway (Cruciat et al., 2013; Gu et al., 2013). Apart from CK1ε, DDX3X also 
has the potential to increase the activity of CK1δ by up to five orders of magnitude, thereby 
representing an important co-factor for CK1-mediated Wnt-specific functions (Cruciat et al., 
2013). Additional interacting proteins were identified in a study screening for interaction 
partners that direct CK1δ to ubiquitinated lesions of Alzheimer’s disease. These all 
contained a common single open reading frame which was termed casein kinase-1 binding 
protein (CK1BP). Sequence alignment demonstrated that CK1BP is structurally homologous 
to the acidic domain of dysbindin, a component of dystrophin-associated protein complex 
(DPC) and biogenesis of lysosome-related organelles complex-1 (BLOC-1). CK1BP inhibits 
CK1δ kinase activity in a dose-dependent manner as demonstrated for the in vitro 
phosphorylation of tau and α-synuclein (Yin et al., 2006). Interestingly, interaction with 
heparin has been reported to activate CK1δ in vitro. Heparin presumably interacts with the 
C-terminal regulatory domain and finally prevents autoinhibition. Although being unlikely 
to represent a physiological regulator of CK1δ kinase activity, experiments performed with 
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heparin impressively demonstrate the autoinhibitory potential of the C-terminal domain 
(Graves et al., 1993; Cegielska et al., 1998).
Dimerization of CK1δ can also be seen as a mechanism for regulation of enzymatic activity 
and is made possible via an extensive dimer interface inside the DD. In more detail, an α-
helix from the CK1δ C-lobe binds to the hydrophobic cavity in the N-lobe of a second CK1δ 
protein (Ye et al., 2016). Finally, the binding of ATP and perhaps also the binding of large 
substrates is prevented by Arg-13 inserting into the adenine binding pocket upon 
dimerization (Longenecker et al., 1998). In solution, CK1δ is always purified as a monomer 
leading to the question if dimerization can actually be considered biologically relevant. 
However, dimerization of CK1δ has been confirmed by studies in which kinase activity of 
endogenous CK1δ was down-regulated by binding of a transfected/transgenic dominant-
negative and less active CK1δ mutant (Hirner et al., 2012). Interestingly, also a kinase-dead 
mutant of CK1ε demonstrated dominant-negative potential, leading to the conclusion that 
dimerization as a regulatory mechanism is not restricted to CK1δ (Cerda et al., 2015). 
Results of a study analyzing the interaction between the yeast (Saccharomyces cerevisiae) 
CK1δ ortholog Hrr25 and the meiosis-specific monopolin subunit Mam1 even led to the 
hypothesis that the hydrophobic dimerization site may be a conserved site for the binding of 
recruiters or regulators in general (Ye et al., 2016).
As a measure to reversibly modulate and fine-tune kinase activity also in the short term, 
CK1δ can be postranslationally modified either by intramolecular autophosphorylation or 
site-specific phosphorylation by upstream cellular kinases (Fig. 6). Generally, CK1 kinase 
activity is decreased upon (C-terminal) phosphorylation and can be regulated in vivo by the 
action of kinases and phosphatases (Rivers et al., 1998). Autophosphorylation processes 
result in the generation of sequences with the motif pSer/pThr-X-X-Y (X stands for any 
amino acid while Y stands for any amino acid except serine or threonine). These motifs can 
subsequently act as pseudo-substrates blocking the catalytic center of the kinase. Within the 
C-terminal domain of CK1δ residues Ser-318, Thr-323, Ser-328, Thr-329, Ser-331, and 
Thr-337 were identified as candidate sites targeted by autophosphorylation (Graves and 
Roach, 1995; Rivers et al., 1998). The presence of an autoinhibitory domain is furthermore 
confirmed by the observation that proteolytic cleavage of the C-terminal domain results in 
increased CK1 kinase activity in vitro (Carmel et al., 1994; Graves and Roach, 1995). As a 
mechanism leading to dephosphorylation of inhibitory C-terminal autophosphorylation sites 
activation of group I metabotropic glutamate receptors (mGluRs) was identified. Following 
activation of mGluRs Ca2+-dependent stimulation of the phosphatase calcineurin finally 
initiates dephosphorylation. Although the underlying study was performed using CK1ε the 
respective target sites are also conserved in CK1δ (Liu et al., 2002).
Within the last decade also site-specific phosphorylation of CK1δ by upstream kinases has 
been extensively described and target sites have been identified. However, most of these 
studies were only performed in vitro and final proof for site-specific phosphorylation in vivo 
is pending in many cases. Within the C-terminal domain of CK1δ Ser-370 could be detected 
as major residue targeted by protein kinase A (PKA), protein kinase B (PKB/Akt), CDC-like 
kinase 2 (CLK2), protein kinase C α (PKCα), and checkpoint kinase 1 (Chk1) (Giamas et 
al., 2007; Bischof et al., 2013; Meng et al., 2016). CK1δ kinase activity was enhanced after 
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mutation of Ser-370 to alanine (S370A) and the key role of Ser-370 was furthermore 
demonstrated in vivo by expressing a S370A mutant of CK1δ in Xenopus laevis embryos. 
By affecting Wnt/β-catenin-mediated signal transduction overexpression of the hyperactive 
S370A mutant led to enhanced formation of an ectopic dorsal axis in Xenopus embryos 
(Giamas et al., 2007).
Apart from Ser-370 site-specific phosphorylation of CK1δ by Checkpoint kinase 1 (Chk1) 
has additionally been identified for Ser-328, Ser-331, and Thr-397. Also for these sites 
mutation to alanine resulted in significantly increased kinase activity (Bischof et al., 2013). 
Ser-328 and Thr-329 were also identified to be targeted by PKCα. Mutation of Ser-328, 
Thr-329, and Ser-370 to alanine significantly affected the kinetic parameters of CK1 and 
resulted in an increase of the catalytic efficiency (kcat/Km) as well, which was most 
impressive for S328A and T329A (Meng et al., 2016).
Cyclin dependent kinase 2/cyclin E (CDK2/E) and cyclin dependent kinase 5/p35 (CDK5/
p35) were also identified as cellular kinases able to modulate CK1δ activity through site-
specific phosphorylation within the C-terminal domain. Phosphorylation of Ser-331 and 
Thr-344 by CDK2/E has been shown by two independent methods, while phosphorylation of 
Thr-329, Thr-347, Ser-356, Ser-361, and Thr-397 finally could not be confirmed. 
Furthermore, no clear evidence could be generated confirming phosphorylation of Thr-329, 
Thr-344, Thr-347, Ser-356, Thr-397 by CDK5/p35 (Ianes et al., 2016). Recently however, 
Eng et al. identified Thr-347 to be phosphorylated by CDKs (Eng et al., 2017).
While most studies focused on the identification of phosphorylation sites in the C-terminal 
domain of CK1δ, potential targeted sites for cellular kinases can also be found in the kinase 
domain. Recent reports demonstrate that residues Ser-53, Thr-176, and Ser-181 can be 
phosphorylated by PKCα (Meng et al., 2019, Bohm et al., 2019). Furthermore, 
phosphorylation of residues Thr-161, Thr-174, Thr-176, and Ser-181 has recently also been 
demonstrated for Chk1 (Bohm et al., 2019). Subsequently performed enzyme kinetic 
analysis and experiments pre-incubating CK1δ with either PKCα or Chk1 led to 
identification of domain-specific effects of PKCα- or Chk1-mediated phosphorylation: 
while kinase activity can be effectively regulated by site-specific phosphorylation within the 
C-terminal domain (Bischof et al., 2013, Meng et al., 2016), phosphorylation events 
occurring in the kinase domain might be involved in fine-tuning kinase activity by regulating 
interactions of the kinase with different substrates or ATP (Bohm et al., 2019, Meng et al., 
2019, Bohm et al., 2019).
When being incubated together with Chk1, PKCα, CDK2/E, or CDK5/p35 the in vitro 
kinase activity of CK1δ is significantly reduced (Bischof et al., 2013; Ianes et al., 2016; 
Meng et al., 2016). While these observations were only generated in vitro, there is also 
evidence from cell culture-based analyses demonstrating inhibitory effects of site-specific 
phosphorylation on CK1δ kinase activity. CK1-specific kinase activity was reduced in the 
fibrosarcoma cell line HT1080 after activating Chk1 by hydroxyurea treatment (Bischof et 
al., 2013). After treating COLO357 pancreatic cancer cells with the PKC-specific inhibitor 
Gö-6983 cellular CK1-specific kinase activity was increased (Meng et al., 2016). A similar 
effect could be observed after treating COLO357 cells with the pan-CDK inhibitor 
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dinaciclib (Ianes et al., 2016). Furthermore, the CDK-targeted phosphorylation sites Thr-344 
and Thr-347 are essential for regulation of CK1δ activity toward period circadian protein 
homolog 2 (PER2) and degradation of PER2 was promoted when Thr-344 and Thr-347 were 
mutated to alanine (Eng et al., 2017).
Although much is known about localization of site-specific phosphorylation of CK1δ, only 
very few studies were performed using low-throughput methods and mechanistic 
investigations. Several phosphorylation sites within CK1δ were only identified by using 
high-throughput approaches and proteome-wide screenings without further analysis of the 
effect of phosphorylation or even the identification of the associated upstream kinase.
By performing proteome-wide analysis also additional posttranslational modifications could 
be identified for CK1δ like ubiquitination (Lys-54, Lys-57, Lys-140, and Lys-263), 
acetylation (Lys-242), and methylation (Arg-335 and Arg-375) (information obtained from 
PhosphoSitePlus®, Hornbeck et al., 2015) (see Fig. 6). However, until now no specific 
functions or effects have been linked to the observed modifications.
Recently, the expression of all three transcription variants in human and mouse was clearly 
shown by using primers specific for TV1, TV2, and TV3, respectively (own unpublished 
results). Furthermore, Michaelis-Menten kinetics clearly revealed that Km and Vmax of the 
three mouse TVs differ in regard to phosphorylation of both, substrates either containing a 
canonical (α-casein) (Fig. 7A and Table 2) or a non-canonical consensus sequence (GST-β-
catenin1–181) (Fig. 7B and Table 2). TV3 is able to phosphorylate α-casein significantly 
stronger than TV1. Moreover, β-catenin is significantly stronger phosphorylated by TV3 in 
comparison to TV1 as well as TV2. These variances could be explained by differences in the 
degree of autophosphorylation mainly occurring within the C-terminal domains of the 
different transcription variants ((Bischof et al., 2012) and Fig. 7C). In addition, it also has to 
be considered that due to sequence differences within their C-terminal regulatory domains 
the presence of consensus sequences for CK1δ targeting kinases is varying, resulting in 
differences of site-specific phosphorylation and consequently, also in altered kinase activity 
(Bischof et al., 2013). Additionally, the phosphorylation state of CK1δ is not only 
modulating kinase activity and functions of the different CK1δ splice variants, it has also 
been shown to influence the binding of specific ATP-competitive inhibitors e.g. resulting in 
different IC50 values associated to different phosphorylation states (Bischof et al., 2012; 
Bischof et al., 2013; Richter et al., 2014).
5. Substrates and substrate recognition
At physiological pH CK1δ carries positive charges at residues Arg-178 and Lys-224, which 
are mainly involved in substrate binding, preferentially enabling interactions with acidic 
substrates. Whereas mammalian CK1 isoforms have so far only been shown to exclusively 
phosphorylate serine and threonine residues of their substrates, the Saccharomyces 
cerevesiae CK1δ homolog Hrr25 and Xenopus laevis CK1α have been shown to 
additionally phosphorylate tyrosine residues (deMaggio et al., PNAS, 1992; Pulgar et al., 
1996). Substrates being primed by previous phosphorylation represent the canonical CK1 
consensus sequence motif pSer/pThr-X-X-(X)-Ser/Thr with X standing for any amino acid 
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and pSer/pThr for the phospho-primed residue. The Ser/Thr residue to be phosphorylated by 
CK1δ is located three to four residues upstream to the primed residue. The primed residue 
can also be replaced by a cluster of negatively charged acidic residues like aspartic (Asp) or 
glutamic acid (Glu) (three or four residues). However, phospho-primed motifs are favored 
over Asp or Glu containing motifs and Asp is favored over Glu (Agostinis et al., 1989; 
Flotow et al., 1990; Flotow and Roach, 1991; Meggio et al., 1991; Graves et al., 1993).
In addition to the canonical consensus motif alternative sequence motifs have been 
identified, which can also represent targets for CK1-mediated phosphorylation. One of these 
motifs is the so-called SLS (Ser-Leu-Ser) motif in which the first serine residue is 
phosphorylated by CK1. This motif can be found in β-catenin and nuclear factor of activated 
T cells (NFAT). In both cases the SLS motif is followed by a cluster of acidic amino acids 
essential for efficient binding to CK1 (Marin et al., 2003). Phosphorylation of β-catenin at 
Ser-45 has been demonstrated for CK1 isoforms α and δ (Amit et al., 2002) while CK1 
isoforms α, δ, and ε co-fractionated with the sensitivity to red light reduced 1 (SRR-1) 
domain of NFAT1 (Okamura et al., 2004). Moreover, the consensus motif Lys/Arg-X-Lys/
Arg-X-X-Ser/Thr has been identified in several sulfatide and cholesterol-3-sulfate (SCS)-
binding proteins, among them myelin basic protein (MBP), the Ras homolog family member 
A (RhoA), and tau. SCS-mediated stimulation of CK1δ-mediated phosphorylation could be 
observed for the two basic brain proteins MBP and tau, and also for the acidic protein RhoA 
(Kawakami et al., 2008).
To date, > 150 substrates have been identified to be phosphorylated by members of the CK1 
family, at least in vitro. Although many substrates can be phosphorylated by more than one 
CK1 isoform and in many cases it is not possible to assign particular isoforms to particular 
substrates, Table 3 aims to list substrates, which were identified to be phosphorylated by 
CK1δ.
6. Subcellular localization of CK1δ and interaction with cellular proteins
In cells CK1δ is distributed within both, the cytoplasm and the nucleus. Increased levels of 
CK1δ can permanently be detected in peri-nuclear regions in close proximity to the Golgi 
apparatus and the trans Golgi network (TGN) (Behrend et al., 2000b; Milne et al., 2001; 
Greer et al., 2014; Stoter et al., 2014). Depending on cellular conditions CK1δ can also be 
temporarily associated to membranes and receptors, transport vesicles, components of the 
cytoskeleton, centrosomes, or spindle poles (Behrend et al., 2000b; Milne et al., 2001; 
Lohler et al., 2009; Greer et al., 2014; Wang et al., 2015). Studies using kinase-dead mutants 
or truncated CK1δ variants demonstrated that the CK1δ kinase domain is required for 
nuclear localization of CK1δ. However, the present nuclear localization signal (NLS) alone 
is not sufficient for nuclear localization. Moreover, not only the presence of a kinase domain 
but also its enzymatic activity is essential for correct distribution of CK1δ within the cell 
(Hoekstra et al., 1991; Graves et al., 1993; Milne et al., 2001). This hypothesis has been 
confirmed for the localization of CK1δ and its yeast ortholog Hrr25 to centrosomes (Milne 
et al., 2001, Peng et al., 2015a, Peng et al., 2015b). However, there are also contradicting 
reports showing that kinase activity is dispensable to target CK1δ to the centrosome (Qi et 
al., 2015; Elmore et al., 2018).
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Further guidance to distinct subcellular compartments is achieved by interaction of CK1δ 
with interacting and scaffolding proteins. These interactions are mediated by docking motifs 
like the Phe-X-X-X-Phe motif, which has been identified in NFAT, β-catenin, and PER 
proteins, or the Ser-Gln-Ile-Pro motif present in microtubule plus-end-binding protein 1 
(EB1) (Vielhaber et al., 2000; Okamura et al., 2004; Bustos et al., 2006; Etchegaray et al., 
2009; Zyss et al., 2011). Although some of these proteins are also substrates for CK1δ-
mediated phosphorylation the docking motifs are not necessarily localized adjacent to the 
phosphorylated residues, but contribute to proper orientation of the interaction partners and 
to stabilization of the interaction (Bustos et al., 2006). Another protein containing the Phe-
X-X-X-Phe interaction motif is family with sequence similarity 83 member H (FAM83H), 
which has originally been identified as a protein involved in the formation of enamel. By its 
interaction with FAM83H nuclear CK1δ is localized to nuclear speckles, which supply 
splicing factors to active transcription sites (Kuga et al., 2016; Wang et al., 2016). FAM83H 
contains four Phe-X-X-X-Phe interaction motifs, one of them located in a conserved domain 
of unknown function (DUF1669). This domain is common to other FAM83 family members 
as well and interactions with CK1δ could also be found for FAM83A, FAM83B, and 
FAM83E (Fulcher et al., 2018). Although FAM83 proteins are substrates for CK1δ-
mediated phosphorylation they are rather considered as regulatory partners directing CK1 
isoforms to specific cellular compartments and substrate pools (reviewed in Bozatzi and 
Sapkota, 2018).
In addition to interaction partners, which have already been mentioned above, numerous 
additional interacting proteins have been described for CK1δ within recent years (Table 4). 
These proteins are not (only) targets for CK1δ-mediated phosphorylation, but are also 
involved in more complex regulatory processes and form strong interactions with CK1δ. 
Apart from the already mentioned scaffolding protein AKAP450 also the Ran-binding 
protein in the microtubule-organizing center (MTOC) (RanBPM) was identified as a 
centrosome-targeted interacting protein for CK1δ. The proteins interacted in a yeast two-
hybrid screen, partially co-localized, and RanBPM was even phosphorylated by CK1δ 
(Wolff et al., 2015). Furthermore, interaction between CK1δ and microtubule-associated 
protein 1A (MAP1A) has been demonstrated by yeast two-hybrid screen and co-
immunoprecipitation. Consequently, microtubule dynamics might be changed via CK1δ-
mediated phosphorylation of the light chain LC2 of MAP1A (Wolff et al., 2005). CK1δ is 
also involved in the regulation of vesicle transport and synaptic functions, underlined by the 
fact that CK1δ interacts with snapin, a protein associated with SNAP25, regulating 
neurotransmitter release in neuronal cells (Wolff et al., 2006). In developmental processes 
CK1δ has been found to interact with the pro-neural basic helix-loop-helix (bHLH) 
transcription factor Atoh1, which plays a key role in sensory hair development. Following 
phosphorylation by CK1δ degradation of Atoh1 is initiated by the E3 ubiquitin ligase 
Huwe1 (Cheng et al., 2016). As another developmental-associated factor also lymphocyte 
enhancer factor (LEF-1) can be bound and phosphorylated by CK1δ, resulting in disruption 
of binding between LEF-1 and β-catenin while DNA-binding of LEF-1 is not impaired 
(Hammerlein et al., 2005). Association of CK1δ has also been reported for the regulatory 
and complex-building/-initiating molecule 14-3-3 ζ, which also interacts with CK1α and 
CK1ε (Dubois et al., 1997; Zemlickova et al., 2004). In order to mediate this interaction 
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CK1δ contains the sequence Leu-Gly-Ser-Leu-Pro, which is quite similar to a putative motif 
described for 14-3-3 binding (Muslin et al., 1996). Finally, almost two decades ago 
interaction between CK1δ and the circadian clock proteins PER and cryptochrome (CRY) 
has been demonstrated by Lee and colleagues. In the circadian cycle CK1 isoforms facilitate 
the translocation of PERs and CRYs to the nucleus (Lee et al., 2001).
7. CK1δ-associated cellular functions
7.1. CK1δ in the circadian rhythm
The circadian rhythm is controlled by the cellular clock, permitting a cellular rhythm of 
approximately 24 h. Alterations in the circadian rhythm could be observed in different 
disorders such as sleeping, metabolic, and neurological disorders, which will be discussed in 
more detail in the following paragraphs (Ferrell and Chiang, 2015; De Lazzari et al., 2018; 
Leng et al., 2019; Stenvers et al., 2019).
The circadian rhythm is characterized by a negative feedback loop mediated by PER and 
CRY proteins, whose expression levels oscillate over the circadian clock. PERs and CRYs 
can form heterodimers, shuttle into the nucleus (Lee et al., 2001; Aryal et al., 2017), and 
inhibit their own expression through the inhibition of the CLOCK/BMAL1-responsive 
circadian gene transcription (Virshup et al., 2007). Once in the nucleus, CK1δ seems to 
enhance the inhibition of circadian-driven transcription by reducing CLOCK/BMAL1 
binding affinity to DNA (Aryal et al., 2017). Since mRNA levels of CK1δ/ε could vary in 
light-induced phase-shift in mice, CK1δ/ε seems to play an important role in balancing the 
circadian rhythm (Ishida et al., 2001). In fact, the regulation of PER degradation is mainly 
influenced by reversible phosphorylation controlled by kinases and phosphatases (so called 
“phosphoswitch”) (Gallego and Virshup, 2007; Virshup et al., 2007). CK1δ and ε are among 
the most important kinases, controlling PER phosphorylation (Camacho et al., 2001; Lee et 
al., 2001; Xu et al., 2005; Narasimamurthy et al., 2018). CK1δ seems to have a more 
important and essential role in the circadian clock compared to CK1ε (Etchegaray et al., 
2009; Walton et al., 2009). When CK1δ is disrupted or inactivated, an elongation in the 
circadian clock has been observed (Etchegaray et al., 2009, Isojima et al., 2009, Lee et al., 
2011b, Mieda et al., 2016), while overexpression of CK1δ leads to a shortening of the 
circadian rhythm (Lee et al., 2009; Mieda et al., 2016). Inhibition of CK1δ/ε by PF-670462 
also has shown inhibitory effects on the expression of clock genes such as Bmal1, Per1, Per2 
and Nr1d1 in rats (Kennaway et al., 2015).
After inhibition of N6-methylation (m6A) of CK1δ mRNA, enhancement of CK1δ 
translation permits the expression of CK1δ TV1 and TV2, which seem to differently 
influence the circadian rhythm, first by acceleration following increased degradation of 
PER2 and secondly by deceleration consequently leading to PER2 stabilization (Fustin et 
al., 2018). Moreover, a recent study identified CK1δ TV2 with a stronger role in priming 
phosphorylation of PER2 compared to CK1δ TV1, which permits subsequent 
phosphorylation events on PER2 (Narasimamurthy et al., 2018).
Robustness of the circadian clock has been analyzed by Nakajima and colleagues, who 
confirmed that the inhibition of PER2 phosphorylation by CK1δ/ε leads to destabilization of 
Xu et al. Page 13













the oscillation (Nakajima et al., 2015). Moreover, CK1δ-mediated phosphorylation of PER2 
seems to be a temperature-insensitive process, being responsible for the robustness of this 
process (Isojima et al., 2009). Nevertheless, the activity of CK1δ in phosphorylating PER2 
seems to be controlled by upstream kinases, likely by cyclin-dependent kinases or proline-
directed kinases, which can phosphorylate CK1δ on Thr-344 or Thr-347, thereby reducing 
its activity (Ianes et al., 2016; Eng et al., 2017). Interestingly, the circadian rhythm seems to 
be coupled with – and also be influenced by – the cell cycle (Unsal-Kacmaz et al., 2005). In 
fact, mutations and deregulation of circadian rhythm components have been observed in 
cancer (Wood et al., 2008).
7.2. CK1δ in DNA damage and cellular stress
Stress-conditions, among them genotoxic stress and DNA damage, lead to p53-dependent 
activation of CK1δ, finally resulting in CK1δ-mediated phosphorylation of key regulatory 
proteins involved in these processes, like p53 and Mdm2 (Knippschild et al., 1997). CK1δ 
phosphorylates p53 within its N-terminal domain on residues Ser-4, Ser-6, Ser-9 
(Knippschild et al., 1997; Higashimoto et al., 2000), and Ser-20 (MacLaine et al., 2008; 
Venerando et al., 2010). When p53 is phosphoprimed on Ser-15 additional CK1δ-mediated 
phosphorylation on Thr-18 results in lower binding affinity between p53 and Mdm2 and 
consequently elevated p53 activity (Dumaz et al., 1999; Alsheich-Bartok et al., 2008). 
Moreover, not only p53 but also its negative regulator Mdm2 can be phosphorylated by 
CK1δ. Under normal conditions, CK1δ-mediated phosphorylation of Mdm2 on Ser-240, 
Ser-242, Ser-246, and Ser-383 stabilizes the Mdm2-p53 complex and consequently leads to 
increased degradation of p53 (Blattner et al., 2002; Winter et al., 2004). Interestingly, REGγ 
(11S regulatory particles, 28-kDa proteasome activator γ) seems to have a role in promoting 
degradation of CK1δ, finally leading to stabilization of Mdm2 protein levels and therefore 
decreased p53 activity (Li et al., 2013). Upon DNA damage, ataxia telangiectasia mutated 
(ATM)-mediated phosphorylation of CK1δ leads to phosphorylation of Mdm2, permitting 
SCFβ-TrCP (skp cullin F-box containing complex beta-transducin repeat containing protein)-
mediated ubiquitination of Mdm2 and its proteasomal degradation (Inuzuka et al., 2010a, 
Inuzuka et al., 2010b, Wang et al., 2012). Under hypoxia, a hypoxia-inducible factor 1 
(HIF-1) heterodimer (HIF-1α and aryl hydrocarbon receptor nuclear translocator (ARNT)) 
can form and activate the transcription of hypoxia-responsive genes. CK1δ plays a role in 
phosphorylating HIF-1α on residue Ser-247, thereby interfering with its binding to ARNT 
and resulting in decreased HIF-1 activity (Kalousi et al., 2010). Interestingly, under hypoxic 
conditions CK1δ can also reduce cell proliferation and lipid droplet formation by reducing 
HIF-1α/ARNT complex formation (Kourti et al., 2015). The activity of topoisomerase II α 
(TOPOII-α), another important regulator of DNA replication and cell division, is also 
influenced by CK1δ-mediated phosphorylation on residue Ser-1106, finally resulting in 
increased TOPOII-α function (Grozav et al., 2009). Furthermore, CK1δ phosphorylates the 
ubiquitin-like containing PHD and RING finger domains 1 protein (UHRF1), which plays 
an important role in the maintenance of DNA methylation during DNA replication. Upon 
DNA damage, enhanced degradation of UHRF1 can be observed due to increased CK1δ-
mediated phosphorylation on Ser-108, permitting binding of the SCFβ-TrCP E3 ligase and 
subsequent proteasomal degradation of UHRF1 (Chen et al., 2013).
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7.3. CK1δ in cell cycle, mitosis, and meiosis
CK1δ was shown to have important roles in microtubule dynamics, cell cycle progression, 
genomic stability, mitosis, and meiosis (Behrend et al., 2000a, Behrend et al., 2000b, 
Sillibourne et al., 2002, Stoter et al., 2005, Johnson et al., 2013, Greer et al., 2014, Penas et 
al., 2014, Penas et al., 2015, Phadnis et al., 2015, Sakuno and Watanabe, 2015, Chan et al., 
2017, Greer et al., 2017). As already mentioned before, CK1δ is anchored to the centrosome 
via its interaction with AKAP450 (Sillibourne et al., 2002), allowing CK1δ-mediated 
phosphorylation of EB1, a component relevant for centrosome positioning during T cell 
activation (Zyss et al., 2011). In order to ensure centrosomal integrity and maintenance of 
genomic stability centrosome-associated CK1δ might also cooperate with a centrosomal 
subpopulation of p53 (Wahl et al., 1996; Meek, 2000; Tarapore and Fukasawa, 2002). 
Consequently, CK1δ/ε play an important role in cell cycle progression as well as in genomic 
stability. Following its inhibition by IC261 cells undergo a transient mitotic arrest (Behrend 
et al., 2000a), even though additional studies reported that cell cycle arrest upon treatment 
with IC261 is a result of severe off-target effects mediated by IC261 (Cheong et al., 2011; 
Stoter et al., 2014). Nevertheless, mouse embryonic fibroblasts (MEFs) lacking CK1δ are 
characterized by multiple centrosomes and the presence of micronuclei, indicators of 
genomic instability (Greer et al., 2017). Accordingly, silencing of CK1δ leads to lower 
amounts of Chk1 and cell division cycle 2 (CDC2)/CDK1, both having important roles in 
DNA damage response and mitotic checkpoints (Greer et al., 2017). Interestingly, Chk1-
mediated regulation of CK1δ as well as their physical binding have previously been shown, 
confirming interaction of CK1δ with Chk1 (Bischof et al., 2013). Moreover, CK1δ-mediated 
phosphorylation of Wee1-G2 checkpoint kinase (Wee1) can lead to its proteasomal 
degradation resulting in increased levels of active CDK1 and the consequent entrance of 
cells into mitosis (Penas et al., 2014). In line with these results, inhibition of CK1δ or its 
destruction after APC/CCdh1 (adenomatous polyposis coli/cyclosome cadherine 1)-
mediated ubiquitination increases the stability of Wee1 kinase, which elevates CDK1 
phosphorylation, leading to cell cycle exit (Penas et al., 2014; Penas et al., 2015). On the 
other hand, CK1δ is also able to phosphorylate phosphoprimed septation initiation protein 4 
(Sid4), thereby initiating the recruitment of Chk2/Cds1 (checkpoint kinase 2/replication 
checkpoint kinase Cds1) and a subsequent mitotic commitment (Chan et al., 2017). On the 
other hand, under mitotic stress, Hhp1 and Hhp2 (Hhp1/2), orthologous forms of CK1 in 
Schizosaccharomyces pombe, have been identified to play an important role in the mitotic 
checkpoint by delaying cytokinesis. By co-localization with spindle pole bodies (SPBs), 
CK1 can phosphorylate Sid4, thereby inducing Dma1-mediated ubiquitination and 
degradation of Sid4, leading to cytokinesis suspension (Johnson et al., 2013; Elmore et al., 
2018). Inhibition of CK1 isoforms by D4476 also increases the mitotic cell rate via 
increased stability of β-catenin and elevated β-catenin-mediated transcription, confirming an 
important role of CK1 in mitosis and cell cycle progression (Benham-Pyle et al., 2016).
Apart from its involvement in mitosis CK1δ also plays an important role in the regulation of 
meiotic processes. CK1δ and its ortholog Hrr25 have been detected within P-bodies, 
cytoplasmic RNA-protein granules present in meiotic cells. This binding seems to reduce 
CK1 turnover into the cytoplasm, thereby preserving protein integrity for subsequent stages 
of meiosis (Zhang et al., 2016; Zhang et al., 2018). Localization of Hrr25 to P-bodies is 
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necessary for completion of the meiotic program (Zhang et al., 2018). Hrr25 has also been 
observed to be involved in the induction of nuclear division of meiosis as well as in the 
synthesis of membranes to engulf newly synthetized nuclei, thereby mediating the exit from 
meiosis II (Arguello-Miranda et al., 2017). In oocytes in metaphase I and in metaphase II 
CK1δ co-localizes with γ-tubulin at the spindle poles (Qi et al., 2015). However, CK1δ 
seems not to be essential for spindle organization and meiotic progression in human cells. 
This is in contrast to earlier studies performed in yeast. Ishiguro and colleagues showed that 
Hhp2, the CK1δ/ε ortholog in S. pombe, acts as cohesion kinase promoting cleavage of the 
cohesion subunit Rec8 (meiotic recombination protein Rec8) during meiosis (Ishiguro et al., 
2010; Katis et al., 2010). This observation is supported by a report from Rumpf and 
colleagues showing that the CK1δ/ε orthologs Hhp1 and Hhp2 in S. pombe are essential to 
achieve full phosphorylation of Rec8 and subsequent efficient removal of Rec8 during 
meiosis I (Rumpf et al., 2010). This data impressively shows that results based on 
investigations in yeast models cannot necessarily be transferred to mammalian cells. 
However, stromal antigen 3 (STAG3), the mammalian ortholog of meiotic recombination 
protein Rec11, is also phosphorylated by CK1, thereby confirming the conservation of this 
process and the observations made in yeast, showing that Rec11 is phosphorylated by Hhp1 
and Hhp2, subsequently permitting DNA breakage and consequent meiotic recombination 
(Phadnis et al., 2015; Sakuno and Watanabe, 2015).
7.4. CK1δ-specific functions associated with cytoskeleton components
Numerous studies report cellular localization of CK1δ to components of the cytoskeleton, 
where CK1δ exercises essential regulatory tasks: CK1δ is able to modulate microtubule 
polymerization and stability at the spindle apparatus and the mitotic centrosome by directly 
phosphorylating α-, β-, and γ-tubulin (Behrend et al., 2000b; Stoter et al., 2005). Not only 
tubulin itself, but also microtubule-associated proteins (MAPs) are interacting with – and are 
phosphorylated by CK1δ, subsequently resulting in modulated interaction of MAPs with 
microtubules and altered microtubule dynamics (Brouhard and Rice, 2018). So far, site-
specific phosphorylation by CK1δ has been demonstrated for MAP4, MAP1A, and tau, as 
well as for the microtubule-destabilizing protein stathmin (Behrend et al., 2000b; Li et al., 
2004; Wolff et al., 2005; Hanger et al., 2007; Leon-Espinosa et al., 2013). Microtubule 
nucleation at the Golgi apparatus was inhibited by siRNA-mediated knock-down of CK1δ. 
Furthermore, the localization of CK1δ to the centrosome plays a crucial role in ciliogenesis: 
based on a study specifically knocking-down CK1δ kinase activity (by either using a CK1δ-
specific inhibitor or specific siRNA) CK1δ has been shown to mediate primary ciliogenesis 
by interaction with AKAP450 proteins as well as by maintaining Golgi organization and 
directed protein trafficking (Greer et al., 2014). This is supported by another study 
suggesting a role for CK1δ in the assembly of primary cilia (Lee et al., 2012). In contrast, 
the same study impressively showed an involvement of the highly related isoform CK1ε in a 
Wnt5a-CK1ε-Dvl2-Plk1-mediated pathway for cilia disassembly.
Ciliogenesis in general can be linked to the activity of distinct cellular signal transduction 
pathways. By compartmentalization of essential signal molecules the cilium has been shown 
to restrain signaling via the canonical Wnt as well as the Hedgehog (Hh) pathway (Rohatgi 
et al., 2007; Corbit et al., 2008; Lancaster et al., 2011). Furthermore, ciliogenesis can be 
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promoted by activity of the Hippo pathway (Kim et al., 2014). In conclusion, with its role in 
direct regulation of ciliogenesis, CK1δ might not only able to directly modulate the activity 
of the Wnt, Hh, and Hippo pathways (see chapters below), but also to indirectly control their 
activity by regulating (dis-)assembly of the primary cilium as a physical signal transduction 
platform used by the mentioned pathways.
7.5. CK1δ in the Wnt pathway
The Wnt signaling pathway plays an important role in developmental processes, 
regeneration, cell proliferation and tissue homeostasis. In many types of cancers alterations 
or mutations in the Wnt pathway have been observed (Clevers and Nusse, 2012; Polakis, 
2012; Nusse and Clevers, 2017; Krishnamurthy and Kurzrock, 2018). Briefly, in absence of 
Wnt ligand, β-catenin is phosphorylated and ubiquitinated by the β-catenin destruction 
complex, leading to its proteasomal degradation. Upon Wnt binding to Frizzled (Fzd), the 
co-receptor LRP5/6 can be phosphorylated by CK1α and glycogen synthase kinase 3 
(GSK3). Subsequently, Axin binds to LRP5/6 and recruits the β-catenin destruction 
complex, permitting higher stability of β-catenin. β-catenin shuttles into the nucleus, 
associates with TCF transcription factor, and induces the transcription of Wnt target genes 
(Clevers and Nusse, 2012; Nusse and Clevers, 2017).
As previously summarized in different focused review articles, CK1 isoforms are involved in 
different ways in the Wnt signaling pathway (Cruciat, 2014; Knippschild et al., 2014; Price, 
2006). CK1δ has been shown to phosphorylate the Wnt pathway components Dishevelled 1 
(Dvl1) as well as Axin, APC, and β-catenin (Amit et al., 2002; Gao et al., 2002; Xing et al., 
2003; Ha et al., 2004). Accordingly, CK1δ was also observed to have an essential role in 
neurite formation and dopaminergic neuron differentiation by phosphorylating Dvl (Bryja et 
al., 2007; Greer and Rubin, 2011). Moreover, CK1δ/ε phosphorylate Dvl2, thereby playing 
an important role for intestinal stem cell (ISC) maintenance. In fact, co-ablation of CK1δ 
and ε leads to the elimination of ISCs (Morgenstern et al., 2017). In addition, CK1δ seems 
to be important for the regulation of planar cell polarity (PCP), which depends on proper 
phosphorylation of planar cell polarity protein Van Gogh-like 2 (Vangl2), mediated by 
CK1δ/ε following Wnt-5a-mediated induction of the non-canonical Wnt signaling pathway 
(Yang et al., 2017).
CK1δ can either (i) positively or (ii) negatively influence the Wnt pathway: (i) CK1δ can 
stabilize β-catenin after the phosphorylation of lipoprotein receptor-related protein 6 (LRP6) 
and the subsequent recruitment of Axin and the β-catenin destruction complex, thereby 
avoiding β-catenin phosphorylation and ubiquitination (Zeng et al., 2005; Wu et al., 2009). 
Moreover, CK1δ/ε activity as well as stability are influenced by the tumor promoter TPA 
(12-O-tetra-decanoylphorbol-13-acetate), which also permits increased binding of β-catenin 
to TCF4E in a CK1δ/ε-dependent manner, resulting in an activation of Wnt target genes (Su 
et al., 2018). (ii) CK1δ negatively influences the Wnt pathway by directly phosphorylating 
β-catenin on Ser-45, thereby priming β-catenin for further GSK3β-mediated 
phosphorylation and subsequent degradation (Amit et al., 2002).
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7.6. CK1δ in the Hedgehog pathway
The Hedgehog (Hh) signaling pathway plays an important role in embryonic development 
by regulating cell differentiation, regeneration, proliferation, and organogenesis. 
Deregulation and mutations of main players of this pathway can influence tumorigenesis and 
cancer development (Jiang and Hui, 2008; Yao and Chuang, 2015; Wu et al., 2017). Briefly, 
in absence of Hh ligand (Sonic Hedgehog (Shh), Indian hedgehog (Ihh), or Desert hedgehog 
(Dhh)) the twelve-pass-membrane receptor Patched (Ptch) inhibits the seven-pass membrane 
receptor Smoothened (Smo). In this context, cubitus interruptus/glioma-associated oncogene 
(Ci/Gli) transcription factor can be phosphorylated, undergoes partial proteasomal 
degradation, and shuttles into the nucleus where it can act as a repressor of Hh-targeted gene 
transcription. Once Hh binds to Ptch, Smo receptor can be phosphorylated and Ci/Gli 
transcription factor can migrate into the nucleus to activate Hh target genes (Jiang and Hui, 
2008; Heretsch et al., 2010; Wu et al., 2017). CK1 isoforms play different roles in the Hh 
pathway. CK1δ has recently been shown to increase Smo activity by phosphorylating Smo at 
Ser-683 after priming phosphorylation mediated by PKC (Jiang et al., 2014). Upon Hh 
stimulation, CK1δ phosphorylates the full-length Cubitus interruptus positive transcription 
factor (CiA), protecting it from proteasomal degradation (Shi et al., 2014). In contrast, site-
specific phosphorylation of Ci by CK1 results in enhanced binding of SCFSlimb E3 ubiquitin 
ligase to Ci, subsequently leading to proteasomal degradation of Ci (Smelkinson et al., 
2007). Additionally, after priming phosphorylation by PKA, CK1 phosphorylates CiA, 
thereby increasing its proteolysis and generation of the repressive form of Ci (CiR) (Price 
and Kalderon, 2002).
7.7. CK1δ in the Hippo pathway
The Hippo pathway is involved in embryonic development to determine organ size by 
influencing cell proliferation, apoptosis, and tissue homeostasis (Zeng and Hong, 2008; Bae 
and Luo, 2018; Moon et al., 2018). Hippo signaling is activated by high cell density. A 
phosphorylation cascade is induced after phosphorylation of mammalian sterile-20 like 
kinase 1/2 (MST1/2), which further phosphorylates large tumor suppressor kinase 1/2 
(LATS1/2), ultimately phosphorylating yes-associated protein (YAP)/tafazzin (TAZ). As 
major downstream target YAP/TAZ can either be ubiquitinated and degraded or retained in 
the cytoplasm after binding to 14–3–3. Under conditions of low cell density, the Hippo-
signaling cascade is not activated and YAP/TAZ is able to translocate into the nucleus and to 
bind TEAD (TEA domain)/SMAD (SMA/mothers against decapentaplegic) transcription 
factors, inducing Hippo target gene transcription for growth and differentiation (Zeng and 
Hong, 2008, Bae and Luo, 2018, Moon et al., 2018). YAP degradation is also influenced by 
CK1δ/ε-mediated phosphorylation on Ser-381, after its priming phosphorylation by LATS 
on Ser-127, which permits the recruitment of the E3 ubiquitin ligase SCFβ-TrCP, 
ubiquitination, and subsequent degradation of LATS (Zhao et al., 2010). Interestingly, the 
Hippo pathway seems to be connected to the Wnt pathway in different ways, for instance by 
interaction of YAP/TAZ with DVL, β-catenin, and the β-catenin destruction complex 
(Varelas et al., 2010; Heallen et al., 2011; Azzolin et al., 2012; Imajo et al., 2012; Rosenbluh 
et al., 2012; Konsavage Jr. and Yochum, 2013; Azzolin et al., 2014; Wang et al., 2018), as 
well as with regulation of p53 (Ferraiuolo et al., 2017; Furth et al., 2018). Hippo signaling 
can negatively influence Wnt signaling via Dvl protein, which in presence of Wnt ligand 
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binding is phosphorylated by CK1δ/ε and inhibits the β-catenin destruction complex. In this 
context, YAP/TAZ binds Dvl, thereby reducing its CK1δ/ε-mediated phosphorylation as 
well as the subsequent transduction of Wnt signaling (Varelas et al., 2010; Imajo et al., 
2012). Moreover, phosphorylated YAP/TAZ is able to bind β-catenin, which is then retained 
in the cytoplasm, resulting in a decreased transcription of Wnt target genes (Heallen et al., 
2011; Imajo et al., 2012). Interestingly, YAP/TAZ have also been identified as downstream 
effectors of the non-canonical Wnt signaling pathway, whose target genes seem to have 
inhibitory potential on canonical Wnt signaling (Park et al., 2015).
8. Involvement of CK1δ in pathological processes
Most studies in regard to the involvement of CK1δ in the development and progression of 
certain diseases and disorders concentrate on the relation of CK1δ to cancer and neurologic 
diseases. Apart from those, also disorders affecting cell cycle, metabolism, and stem cell 
functions associated with CK1δ are another main topic. Furthermore, metabolic diseases as 
well as inflammatory and infectious diseases related to CK1δ-specific functions are also 
reported in some studies and will be discussed in the following sections.
8.1. CK1δ in tumorigenesis and tumor progression
Cancer-associated functions of CK1δ are closely related to the above described roles of 
CK1δ in Wnt/β-catenin-, p53-, Hh-, and Hippo-related signaling. Meanwhile numerous 
studies described the oncogenic features of CK1δ in different types of cancer. These include, 
among others, gastrointestinal tumors, breast cancer, kidney cancer, hematological 
malignancies, and skin cancer. A database research analyzing microarray datasets generated 
from the analysis of certain tumor cell lines and tumor tissues revealed that CK1δ mRNA is 
overexpressed in many cancer types like bladder cancer, brain cancer, breast cancer, 
colorectal cancer, kidney cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, 
and prostate cancer, as well as in hematopoietic malignancies (Fig. 8 and Table 5) (Schittek 
and Sinnberg, 2014).
Animal experiments and cell culture-based analysis confirmed increased expression of 
CK1δ in cells of hyperplastic B cell follicles and B cell lymphoma in p53-deficient mice, but 
also in choriocarcinoma cells and pancreatic ductal adenocarcinoma (Maritzen et al., 2003; 
Stoter et al., 2005; Brockschmidt et al., 2008). The function of CK1δ in lymphoid 
neoplasms was first described using a mouse model leading to the observation that the 
expression level of CK1δ is increased in cells of hyperplastic B follicles and advanced B cell 
lymphomas in p53-deficient mice. Later, CK1δ mRNA and protein levels were also 
analyzed in 18 lymphoma cell lines and strong expression of CK1δ could be found in all 
analyzed cell lines (Maritzen et al., 2003; Winkler et al., 2015).
Interestingly, in some other studies low expression of CK1δ in cancer tissues has also been 
described (Fig. 8 and Table 5). Decreased expression levels of CK1δ may result in cell cycle 
arrest and apoptosis in various cancer cell lines. These effects are independent of Wnt/β-
catenin-mediated signal transduction. However, they seem to depend on activation of RAS 
and inactivation of p53 (Cheong et al., 2011; Cheong and Virshup, 2011). Decreased activity 
of CK1δ has also been characterized in SV40-transformed cells in vitro and in SV40-
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induced mammary carcinogenesis in a bitransgenic mouse model in vivo. In this model 
CK1δ kinase activity is impaired by site-specific mutations (e.g. N172D) and transgenic, 
mutant CK1δ exercises a dominant-negative effect on endogenous CK1δ. The resulting 
partial inhibition of CK1δ activity reduced transformation of SV40-transformed cells, 
decelerated tumor progression, and prolonged survival of WAP-mutCK1δ/WAP-T 
bitransgenic mice (Hirner et al., 2012). In contrast, the R324H mutation in the C-terminal 
region of CK1δ is associated with increased oncogenic potential and results in promotion of 
the development of adenomas in the intestinal mucosa (Tsai et al., 2007). Furthermore, the 
T67S mutant identified in colorectal cancer tissue exhibits increased kinase activity also 
resulting in higher oncogenic potential. Overexpression of CK1δT67S leads to enhanced 
colony formation of HT29 cells and increased tumor formation in xenografts (Richter et al., 
2015).
Studies on the analysis of a correlation of CK1δ and the overall survival of cancer patients 
revealed that high expression levels of CK1δ are associated with shorter patient survival in 
glioblastoma, lung cancer, and colorectal cancer patients (Schittek and Sinnberg, 2014; 
Richter et al., 2016). In contrast, a high expression of CK1δ with longer patient survival 
time can be found in breast cancer, chronic lymphocytic leukemia, and astrocytic glioma 
patients (Schittek and Sinnberg, 2014).
8.2. Neurologic diseases and disorders
Immunohistochemistry and gene expression studies have demonstrated that CK1 isoforms 
are expressed to a different extend in various parts of the nervous tissue (Schwab et al., 
2000; Camacho et al., 2001; Yasojima et al., 2001; Chergui et al., 2005; Lohler et al., 2009). 
Other studies have been conducted to examine the relationship of CK1δ in brain tissue to 
specific pathological hallmarks by immunohistochemistry. Those studies found that CK1δ is 
associated with the corresponding specific pathological hallmarks of Alzheimer’s disease 
(AD), Down syndrome (DS), progressive supranuclear palsy (PSP), parkinsonism dementia 
complex of Guam (PDC), Pick’s disease (PiD), pallido-ponto-nigral degeneration (PPND) 
(Schwab et al., 2000), and familial advanced sleep phase syndrome (FASPS) (Xu et al., 
2005; Ebisawa, 2007).
Alzheimer’s disease is a progressive neurodegenerative disease characterized by two specific 
brain lesions. One lesion is described by the appearance of neurofibrillary tangles (NFTs), 
abnormal neurites, known as neuropil threads, and neuritic plaques (NPs) in nerve cells 
(Buee et al., 2000). The second lesion is represented by granulovacuolar degeneration bodies 
(GVBs) formed in the hippocampus (Okamoto et al., 1991). Filaments of accumulated 
microtubule-associated tau protein can be considered as reliable marker for neurofibrillary 
degeneration (Flament et al., 1990). Localization analysis of CK1δ in pathological tissue of 
patients with Alzheimer’s disease revealed that the highest expression levels of CK1δ in 
pathological tissues can be detected in GVBs, and the second highest levels were detected in 
NPs. Low CK1δ expression levels could be detected in NFTs. In addition, hippocampal 
expression levels of CK1δ in Alzheimer’s patients were higher than in the control group. 
Interestingly, analysis of expression levels of CK1δ in different organs of AD patients 
revealed that elevated levels of CK1δ could only be found in the brain but not in peripheral 
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organs. In brain tissue, the expression levels of CK1δ are remarkably increased in brain 
areas with increased tau pathology, while the expression levels of CK1δ are modestly 
elevated in areas with low NFT burden (Yasojima et al., 2000). Moreover, co-localization 
studies confirmed that CK1δ is co-localized with its interaction and substrate protein tau in 
the specific pathological tissue lesions like NFTs or GVBs (Schwab et al., 2000).
Typically, NFTs are composed of aggregated filaments formed by hyperphosphorylated tau. 
Tau can be phosphorylated by CK1δ at Ser-202, Thr-205, Ser-396, and Ser-404 in vitro. 
Furthermore, exogenous expression of CK1δ in HEK293 cells induced tau phosphorylation 
and resulted in reduced binding of tau to microtubules (Li et al., 2004). Mass spectrometry-
based analysis of tau phosphorylation revealed that CK1δ and GSK3β are responsible for 
phosphorylation of most sites detected in hyperphosphorylated tau protein and that CK1δ 
together with GSK3β might play an important role in the pathogenesis of AD (Hanger et al., 
2007). Therefore, CK1δ could be a potential target for AD treatment and recently, different 
inhibitors have been developed and may be therapeutically useful in the future. Interestingly, 
[11C]-labeled CK1 inhibitors have been developed as derivatives of already published 
difluoro-dioxolo-benzoimidazol-benzamide compounds (Richter et al., 2014), and have been 
used as radiotracers for CK1 in positron emission tomography (PET) imaging for both, 
diagnosis and therapeutic follow up (Gao et al., 2018). TDP-43 (transactive response DNA-
binding protein of 43 kDa) has been characterized as a hallmark of frontotemporal lobar 
degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) (Amador-Ortiz et al., 2007; 
Bigio, 2011). Moreover; some studies have also shown that TDP-43 is deposited in GVBs 
and can also be strongly associated with the clinical phenotype of AD. Here, TDP-43 
contributes to the AD neurodegenerative process through beta-amyloid (Aβ)-dependent and 
Aβ-independent pathways (Chang et al., 2016). The relationship between CK1δ and TDP-43 
is first reflected in their localization to GVBs. Moreover, by studying different stages of 
granulovacuolar degeneration the increased distribution areas of TDP-43 in brain lesions 
were found to be consistent with the distribution of CK1δ (Thal et al., 2011). In ALS, 
phosphorylation of TDP-43 by CK1δ has been indicated in vitro and by liquid 
chromatography-ion trap mass spectrometry (LC–MS/MS), thereby identifying 29 sites 
within TDP-43 being targeted by CK1δ (Kametani et al., 2009). TDP-43 intracellular 
accumulation and mislocalization seems to be influenced by CK1δ-mediated 
phosphorylation (Nonaka et al., 2016). Accordingly, inhibition of CK1δ-mediated 
phosphorylation of TDP-43 by different CK1δ inhibitors in a neuronal cell model as well as 
in a Drosophila model resulted in prevention of neurotoxicity and rescue of cells from cell 
death (Alquezar et al., 2016). Recently, a newly developed CK1δ inhibitor (IGS3.27) could 
also reduce phosphorylation of TDP-43 and additionally led to normalization of TDP-43 
translocation (Posa et al., 2018). Therefore, CK1δ seems to be an interesting target of 
inhibition for ALS therapy concepts and a lot of effort has been made to improve CK1δ-
selectivity as well as permeability of CK1δ-specific inhibitors through the blood-brain-
barrier (BBB) (Alquezar et al., 2016; Joshi et al., 2016; Wager et al., 2017). Interestingly, the 
FDA-approved drug riluzole, which is already used as a clinical treatment for ALS, can 
inhibit CK1δ/ε, even though with a quite high half maximal inhibitory concentration (IC50) 
value (~16 μM) (Bissaro et al., 2018).
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CK1δ is also involved in Parkinson’s disease (PD) as indicated by its ability to 
phosphorylate α-synuclein, one of the main component of Lewy bodies (LB), on Ser-87 and 
Ser-129 (Okochi et al., 2000). However, priming phosphorylation of α-synuclein on Tyr-125 
seems to be necessary for CK1δ-mediated phosphorylation on Ser-129 (Kosten et al., 2014). 
Different mutations of α-synuclein have been characterized in PD, among them E46K, 
which seems to enhance Ser-129 phosphorylation (Mbefo et al., 2015).
Familial advanced sleep phase syndrome (FASPS) is a circadian rhythm sleeping disorder 
(CRSD) characterized by very early sleep onset and offset, as well as by a short τ period (the 
period in which behavior continues to oscillate in the absence of external cues) (Jones et al., 
1999). The mammalian clock protein PER2 plays a key role in the regulation of circadian 
rhythms in FASPS. Etiology studies carried out by screening patients’ genes detected a 
missense mutation (T44A) in the PER2-binding domain of human CK1δ or a S662G 
mutation in the clock gene PER2 to be causative for FASPS (Xu et al., 2005; Xu et al., 
2007). Introduction of human CK1δ T44A changed the circadian rhythm in both, transgenic 
Drosophila and transgenic mice. However, only changes observed in the mouse model were 
similar to the shortened circadian period observed in human. Changes observed in transgenic 
Drosophila were associated with a lengthened circadian period (Xu et al., 2005). A 
subsequently performed study confirmed in vivo phosphorylation of PER2 by CK1δ at 
Ser-662. Following site-specific phosphorylation of PER2 at Ser-662 the protein is 
characterized by increased stability and longer half-life compared to non-phosphorylated 
PER2 (Shanware et al., 2011). Hyeong-Min Lee and colleagues could show that orchestrated 
action of CK1δ and protein phosphatase 1 (PP1) can determine cell circadian periodicity 
thorough their influence on PER phosphorylation state. In CK1δ/ε-deficient fibroblasts, 
PER phosphorylation was significantly reduced and cell rhythm disappeared. In contrast, 
inhibition of PP1 is able to induce high phosphorylation levels of PER resulting in shortened 
cell rhythm (Lee et al., 2011a). Furthermore, different multi-phosphorylation site mutants of 
CK1δ were characterized to have different activity on PER2 stability, while the most 
significant impact on PER2 stability was observed for the CK1δ T347A mutant. These 
results indicate that PER2 stability can be influenced by site-specific phosphorylation of 
CK1δ at Thr-347, performed by other intracellular kinases (Eng et al., 2017).
8.3. CK1δ in the mediation of drug addiction
Via modulation of the circadian rhythm-regulating PER proteins or the dopaminoceptive 
signal integrator dopamine and cAMP-regulated neuronal phosphoprotein 32 (DARPP-32), 
CK1δ (but also CK1ε) can be involved in the development of drug addiction (Nairn et al., 
2004; Falcon and McClung, 2009). Certain mutations in the gene coding for PER2 proteins 
have previously been linked to conditioned place preference (CPP) of cocaine and increased 
alcohol consumption, highlighting the role of PER2 in the development of addictive 
behavior (Abarca et al., 2002; Spanagel et al., 2005). Using the CK1δ/ε-specific inhibitor 
PF-670462 relapse-like alcohol consumption in rats could successfully be prevented by 
centrally mediated modulation of PER2 phosphorylation (Perreau-Lenz et al., 2012).
The neurotransmission integrator protein DARPP-32 is involved in mediating the motoric 
and rewarding effects of drugs like heroin (Fernandez et al., 2006; Mahajan et al., 2009). 
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Following activation of dopamine D1 receptors by heroin PKA-mediated phosphorylation of 
DARPP-32 is induced, finally leading to inhibition of PP1 by phosphorylated DARPP-32 
and subsequent increase in drug-related rewarding properties (Fernandez et al., 2006). In this 
pathway CK1δ and ε can be involved by phosphorylating DARPP-32 at Ser-130, resulting in 
increased phosphorylation of Thr-34 by PKA and subsequent DARPP-32/PP1 signaling 
(Nairn et al., 2004; Svenningsson et al., 2005). Also here, treatment with the CK1δ/ε-
specific inhibitor PF-670462 attenuated methamphetamine-induced locomotor activity by 
inhibition of DARPP-32 phosphorylation mediated by CK1δ and ε (Bryant et al., 2009). 
Furthermore, treatment with the highly potent CK1δ/ε-specific inhibitor PF-5006739 
resulted in attenuation of drug-seeking behavior in rats trained to self-administer the 
synthetic opioid fentanyl (Wager et al., 2014). In conclusion, specific inhibitors of CK1δ 
(and ε) might be of future use for the treatment of drug addiction or alcohol abuse.
8.4. Metabolic diseases
Apart from sleeping disorders also the onset and severity of metabolic diseases, including 
obesity and type 2 diabetes, can be linked to circadian clock disorders. Therefore, as a key 
regulator of the circadian clock, CK1δ can also affect metabolic dysfunction and can serve 
as promising drug target. In this context, glucose tolerance was improved by daily 
administration of a CK1δ- (and ε-)specific inhibitor (PF-5006739) to mice in a model for 
diet-induced obesity or in a genetic mouse model for obesity (ob/ob) (Cunningham et al., 
2016). CK1δ can furthermore be linked to circadian metabolic regulation via PGC-1α 
(peroxisome proliferator-activated receptor γ co-activator 1α), a transcriptional coactivator 
coordinating circadian metabolic rhythms by simultaneously regulating the expression of 
metabolic and clock genes. Phosphorylation of PGC-1α by CK1δ enhances its proteasomal 
degradation, thereby inhibiting the transcriptional function of PGC-1α in cultured 
hepatocytes, resulting in decreased gluconeogenesis gene expression and glucose secretion 
(Li et al., 2011b). In contrast to this observation, the treatment of a human adipocyte cell line 
with CK1δ-specific inhibitors resulted in increased basal and insulin-stimulated glucose 
uptake (Xu et al., 2015). Xu and colleagues reported that the expression of adiponectin, an 
important adipokine secreted by adipose tissue, was associated with CK1δ expression in 
adipose tissue of morbidly obese patients. Furthermore, in vitro studies revealed that Ser-174 
and Thr-235 of adiponectin are phosphorylated by CK1δ in vitro, contributing to modulation 
of the ability of adiponectin to form biologically active high molecular complexes (Xu et al., 
2015).
8.5. Hijacking of mammalian CK1 pathways by CK1s from parasites
There is increasing evidence suggesting that CK1 is associated with infectious diseases by 
the manipulation of host cell CK1 signaling pathways by intracellular parasites, mediated 
through the export of their own CK1 into the host cell (Sacerdoti-Sierra and Jaffe, 1997; 
Silverman et al., 2010a; Silverman et al., 2010b; Dorin-Semblat et al., 2015; Jiang et al., 
2018). Their survival depends on their ability to subvert the host cell to acquire nutrients or 
to evade the immune response (Lamotte et al., 2017). For instance, Leishmania resides in the 
parasitophorous vacuole of macrophages from where it modifies macrophage biology and 
attenuates the immune response (Lamotte et al., 2017). Plasmodium infects red blood cells 
(RBCs), and modifies their cell membrane to favor the adhesion of the infected RBCs to the 
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vascular endothelium and thus avoid clearance by the spleen (Zhang et al., 2015b). In these 
two parasites, CK1 has been shown to be excreted and could thus contribute to the 
reprogramming of the respective host cells (Sacerdoti-Sierra and Jaffe, 1997; Silverman et 
al., 2010a; Dorin-Semblat et al., 2015). The identified host functions of parasitic CK1s 
imply that these kinases could replace mammalian CK1s to ensure similar functions, 
including phosphorylation of human CK1 substrates and regulation of human CK1 signaling 
pathways (Liu et al., 2009). The BLAST and reverse BLAST of the parasitic CK1s with 
human CK1 shows that they are closely related to human CK1 (see Supplementary Fig. 2 for 
alignment). More specifically, these kinases display a higher level of identity toward human 
CK1δ TV1, suggesting that they might be preferentially hijacking the functions of this 
paralog. The protein sequences of these orthologs is absolutely conserved within each 
different species for Trypanosoma brucei, Trypanosoma cruzi, Plasmodium, and Leishmania 
(Rachidi et al., 2014). This finding suggests that there is a strong evolutionary selection 
pressure to maintain the protein sequence unchanged and as closely related to its human 
counterpart as possible.
The protein organization of parasitic CK1s is very similar to that of human CK1δ. Indeed, 
all the residues involved in ATP binding, the gatekeeper (Met-82), the DFG, the KHD, and 
the SIN motifs, as already defined in Fig. 5, are conserved, suggesting that they are crucial 
for CK1 function. In contrast, other motifs like the CLS are less conserved. The glycine-rich 
ATP binding loop is conserved in all the selected CK1 sequences, except for TcCK1. The 
amino acid substitution present in TcCK1 does not affect ATP binding as those residues are 
conserved, but instead its potential regulation is affected. Indeed, the GSGSFG domain is 
replaced by GAGSFG in TcCK1. However, in Leishmania CK1.2, the two serines of this 
motif are phosphorylated during differentiation, suggesting that they could have a regulatory 
effect for LmCK1.2 ((Tsigankov et al., 2014) and own unpublished data); in Trypanosoma 
brucei, Plasmodium falciparum, and in Toxoplasma gondii, the first serine of the motif is 
phosphorylated (Nett et al., 2009; Treeck et al., 2011). However, despite phosphorylation of 
the glycine triad during differentiation, it has been shown that LmCK1.2 is still active, 
although its activity is lower after differentiation (Rachidi et al., 2014). The catalytic loop 
motif represents a domain for which a T. cruzi-specific substitution has been identified. In 
all parasitic CK1s except for T. cruzi the motif DVKPDN (present in human CK1δ) is 
replaced by the motif DIKPDN, which is similar to that of human CK1α. In T. cruzi CK1 
the human motif is replaced by the motif DMKPDN. These changes could be important, as 
they seem to be conserved. Altogether, these findings indicate that parasitic CK1s are 
closely related to CK1δ, but additionally have characteristics of CK1α and CK1ε.
However, still very little is known about the functions of these kinases in the parasites and 
more importantly about their functions in the host cell. The most studied CK1s are that of 
Plasmodium and Leishmania:
Plasmodium falciparum has only one CK1, PfCK1 (PF3D7_1136500), which presents 69% 
of identity with human CK1 in the kinase domain (Barik et al., 1997). PfCK1 was shown to 
be essential for completion of the asexual intra-erythrocytic cycle (Solyakov et al., 2011). It 
is expressed throughout blood stage, localizes in the parasite but also in the host red blood 
cell, especially associated to the surface of the RBC during the first step of infection (Dorin-
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Semblat et al., 2015). Indeed, data from Magowan et al. suggests that PfCK1 could be 
phosphorylating protein 4.1 and the mature-parasite-infected erythrocyte surface antigen 
(MESA), two components of the erythrocyte membrane skeleton (Magowan et al., 1998). 
Moreover it has been shown to be secreted in the culture medium. This finding suggests that 
PfCK1 could be involved in priming other RBCs for subsequent invasion (Dorin-Semblat et 
al., 2015). A study of the PfCK1 interactome indicates that, similarly to other CK1s, it has 
multiple binding partners and thus regulates multiple pathways, including transcription, 
translation, and protein trafficking. Finally, PfCK1 function is likely to be essential for 
parasite proliferation in erythrocytes.
Leishmania donovani has six CK1 paralogs. Two paralogs, LdBPK_351020.1 and 
LdBPK_351030.1 (LmCK1.2), are closely related (67% identity), but mainly differ within 
their C-terminal domains (Martel et al., 2017). They display the highest identity to human 
CK1. Recently, Martel et al. showed that LdBPK_351020.1 is not essential for parasite 
survival and could have a role during stationary phase (Martel et al., 2017). The four other 
paralogs, LdBPK_303530.1, LdBPK_251640.1, LdBPK_041230.1, and LdBPK_271680.1, 
are extremely divergent from the first two (Rachidi et al., 2014). Little is known about the 
functions of the six paralogs, except for LdBPK_271680.1, which contains an excretion 
signal and is important for regulating growth of cultured parasites and virulence (Dan-Goor 
et al., 2013), and LdBPK_351030.1, which is the most abundant CK1 in Leishmania and the 
only paralog described as having a function in the host cell (Rachidi et al., 2014; Silverman 
et al., 2010a). LdBPK_351030.1 (LmCK1.2) is active in both, promastigotes and 
amastigotes, and can be inhibited by D4476, a CK1-specific inhibitor (Rachidi et al., 2014). 
LmCK1.2 seems to have been selected for its capacity to interact with and phosphorylate 
host proteins to modulate macrophage-mediated processes to favor the survival of the 
parasite. Four pieces of evidence support this hypothesis: (i) LmCK1.2 is released into 
extracellular compartments inside vesicles (Silverman et al., 2010a), (ii) LmCK1.2 is strictly 
conserved between Leishmania species and closely related to human CK1δ, (iii) Leishmania 
CK1 phosphorylates human interferon alpha/beta receptor 1 (IFNAR1), which leads to the 
attenuation of the cellular response to interferon alpha (Liu et al., 2009), and (iv) LmCK1.2 
is essential for Leishmania intracellular survival in the mammalian host. Little is known 
about the functions of LmCK1.2 in the parasite, as only few substrates have been found, 
among them heat shock proteins 90 and 70 (Hsp90 and Hsp70), and no interaction partners 
((Hombach-Barrigah et al., 2019) and Martel et al., manuscript in preparation). LmCK1.2 is 
sensitive to known human CK1 inhibitors and is inhibited by CKI-7, IC261, and D4476 
(Rachidi et al., 2014). Interestingly, results obtained for IC261 (IC50 of 10 μM for LmCK1.2 
versus 4.8 μM for mammalian CK1) suggest that the ATP binding pocket of LmCK1.2 might 
be structurally closer to that of CK1α than to that of CK1δ (Rachidi et al., 2014). As 
Leishmania CK1 is essential for parasite survival in the macrophage, it constitutes a perfect 
target for anti-leishmanial therapy. Several screens looking for small molecules able to 
inhibit LmCK1.2 and thus kill the parasites were performed and despite the high identity to 
human CK1, small molecules were identified to more specifically target Leishmania CK1 
(Allocco et al., 2006; Marhadour et al., 2012; Durieu et al., 2016).
Altogether, by being exported into the host cells, parasitic CK1s take over functions 
normally performed by human CK1. Studying these orthologs could bring more knowledge 
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on the functions of human CK1s and lead to new therapeutic strategies preventing hijacking 
of the host cell by parasites.
9. Modulating CK1δ activity
Recently, interest in modulating the activity of CK1δ has increased enormously. The main 
focus is directed to the development of highly effective small molecule inhibitors (SMIs) 
since deregulation of CK1δ expression and activity levels contributes to the pathogenesis of 
severe disorders, among them cancer and neurologic diseases like AD, PD, ALS, and 
sleeping disorders. However, due to the existence of several highly conserved CK1 isoforms 
(CK1α, γ1–3, δ, ε) with overlapping or opposed physiological and pathophysiological 
functions, it is very challenging to design SMIs being selective for CK1δ only. Furthermore, 
there is increasing evidence that posttranslational modifications of CK1δ, especially site-
specific phosphorylation within its C-terminal regulatory domain, modulates the efficiency 
of SMIs (Bischof et al., 2012; Bischof et al., 2013; Richter et al., 2014). It is also very 
challenging and of high clinical interest to develop SMIs with higher affinity toward CK1δ 
mutants with increased oncogenic potential since their use would expand the therapeutic 
window and decrease the occurrence of severe side effects enormously.
Within the last 30 years more and more CK1-specific SMIs have been developed. Since 
most of the compounds described so far are classified as ATP-competitive inhibitors (type I 
inhibitors), it cannot be excluded that due to structural similarities within the ATP binding 
site additional kinases and other ATP binding proteins are also inhibited to some extent.
Whereas the first CK1 inhibitor, CKI-7 (N-(2-aminoethyl)-5-chloroisoquinoline-8-
sulfonamide), did not show any CK1 isoform-specificity (Chijiwa et al., 1989), IC261 
(3-[(2,4,6-trimethoxyphenyl)-methylidenyl]-indolin-2-one) (Mashhoon et al., 2000) and 
D4476 (4-[4-(2,3-dihydro-benzo)[1,4]dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]-
benzamide) (Rena et al., 2004) exhibit a higher selectivity toward CK1δ and ε. Although 
CK1δ/ε-specific inhibition by IC261 affects site-specific phosphorylation of Bid and 
induces apoptosis in tumor cells (Izeradjene et al., 2004), several cellular effects of IC261 
are not due to inhibition of CK1δ/ε. Among these effects are the inhibition of microtubule 
polymerization, which is due to the direct binding of IC261 to tubulin (Cheong et al., 2011; 
Stoter et al., 2014), and the blocking of voltage-gated sodium channels, which are implicated 
in tumor progression (Fohr et al., 2017). Furthermore, due to the fact that many CK1-
specific inhibitor compounds are classified as ATP-competitive inhibitors (type I inhibitors) 
comparison of their efficacy is difficult since their IC50 values have been assessed at 
different ATP concentrations (Supplementary Table 1) (reviewed in Knippschild et al., 
2014).
Several structure-based virtual screens resulted in the identification of various CK1δ-specific 
inhibitors, among them amino-anthraquinone analogues (Cozza et al., 2008), N6-phenyl-1H-
pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives (Yang et al., 2012), and the 
dihydroxyquinoline sulphonamide NSC45572 (Myrianthopoulos et al., 2017). A group-
based quantitative structure and activity relationship (GQSAR) model based on N-
benzothiazolyl-2-phenyl acetamide derivatives (Salado et al., 2014) was generated by Joshi 
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and co-workers. Using this model, site-specific molecular fragments of individual 
compounds allow for the interpretation of observed differences in the biological activity of 
these compounds. Compounds identified using this approach could be used as lead 
substances against CK1δ, able to block CK1δ-mediated site-specific phosphorylation of 
TDP-43 and might be useful for developing new therapeutic concepts for the treatment of 
ALS (Joshi et al., 2016).
In addition, several benzimidazole-based CK1-specific inhibitors have demonstrated their 
potential to specifically inhibit CK1δ and ε (SR-3029 and SR-2890 (Bibian et al., 2013); 
Bischof-5 and Bischof-6 (Bischof et al., 2012); Richter-2 (Richter et al., 2014); IWP-2, 
IWP-4, and compound 19 (Garcia-Reyes et al., 2018)). Although Bischof-5, a 2-benzamido-
N-(1H-benzo[d]imidazol-2-yl)thiazole-4-carboxamide derivative with a trifluoromethyl 
substitution on the phenyl ring, exhibits IC50 values toward rat CK1δ and human CK1δ 
transcription variants 1 and 2 between 22 and 42 nM, its ability to inhibit proliferation of 
various tumor cell lines is limited (Bischof et al., 2012). However, the specificity, activity, 
and anti-proliferative activity has further been increased by a difluoromethyldioxolo group 
on the benzimidazole, finally leading to the development of Richter-2 (IC50 CK1δ = 0.14 
μM vs. IC50 CK1ε = 0.52 μM (Richter et al., 2014)).
Optimization of benzimidazole derivatives by Bibian and coworkers included enhancement 
of the interaction of compounds with Arg-13 of CK1δ, thereby reducing off-target effects by 
altering the substituents on the benzimidazole unit (either R1 or R2) and increasing 
inhibition of CK1δ, which could be achieved by using piperazine or N-methyl piperazine as 
R4 and thiophene, furan, and 3-fluorophenyl groups as R3. These modifications finally 
resulted in development of the highly CK1δ/ε-selective inhibitors SR-2890 and SR-3029 
with improved inhibitory and anti-proliferative features (Bibian et al., 2013).
Interestingly, due to structural similarities to benzimidazole-based CK1 inhibitors, especially 
to Bischof-5 (Bischof et al., 2012), inhibitors of Wnt production (IWPs), known to be 
antagonists of the Wnt pathway by preventing Wnt ligand palmitoylation through inhibition 
of the membrane-bound O-acyltransferase porcupine (Porcn), have recently been described 
to specifically inhibit CK1δ. This led to the development of improved IWP-based ATP-
competitive inhibitors of CK1δ and to the conclusion that the effects observed for IWPs are 
not only due to Porcn inhibition, but also to effects on CK1δ/ε-related signaling (Garcia-
Reyes et al., 2018).
Quite recently, [11C] labeled highly potent difluoro-dioxolo-benzoimidazol-benzamides have 
been generated, which have a high potential to be prognostically used as PET radiotracers 
for imaging of AD (Gao et al., 2018).
Several additional small molecule inhibitors, which have been described to exhibit dual 
specificity, will be introduced in the following paragraph. Compound (R)-DFR053 
((R)-2-(1-hydroxybut-2-ylamino)-6-[3-(2-pyridyl)phenylamino]-9-isopropylpurine), a 
roscovitine derivative, specifically targets CK1δ and CDK5, and could be useful for the 
analysis of pathways involved in neurodegeneration and therapeutic applications in AD 
(Oumata et al., 2008). The pyrazolo-pyridine analogues MRT00055778 (N1-[4-(5-methyl-3-
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phenylisoxazol-4-yl)pyrimidin-2-yl]acetamide) and MRT00033659 (5-(3-
acetamidophenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine) have been shown to inhibit CK1δ 
and Chk1, finally resulting in stabilization of the p53 pathway (Huart et al., 2013). In 
addition, the Clk-specific inhibitor TG003, a benzothiazole derivative (Muraki et al., 2004), 
has been described to inhibit Clk and CK1 isoforms in a mouse model for mechanical 
allodynia and thermal hyperalgesia (Kurihara et al., 2014). Based on structural similarity 
between N-(benzo[d]thiazol-2-yl)-2-phenylacetamide derivatives with CK1 inhibitory 
activity and 1-(benzo[d]thiazol-2-yl)-3-phenylureas which have been designed as Aβ-
binding alcohol dehydrogenase (ABAD) inhibitors, several benzothiazolylphenylureas could 
be identified as dual-specific inhibitors, among them K690 and K691, presenting an 
interesting class of dual-specific anti-AD therapeutics (Benek et al., 2018).
Several diaryl-isoxazoles and -imidazoles have been described as dual inhibitors against 
p38α MAPK and CK1δ/ε. Whereas PF-670462 (4-[3-cyclohexyl-5-(4-fluoro-phenyl)-3H-
imidazol-4-yl]-pyrimidin-2-ylamine) possesses only poor CK1 isoform selectivity 
compound PF-4800567 exhibits a much stronger inhibition of CK1ε than CK1δ (Badura et 
al., 2007; Walton et al., 2009).
Seerden and colleagues could demonstrate structure-activity relationship of 4-(40-
fluorophenyl)imidazoles as specific inhibitors of p38α MAPK, CK1δ, or JAK2 with IC50 
values lower than 100 nM (Seerden et al., 2014).
In addition, substituted isoxazoles 1 and 2 with the typical vicinal pyridin-4-yl/4-F-phenyl 
pharmacophore (Peifer et al., 2009), which have been originally generated and characterized 
as ATP-competitive inhibitors for p38α MAPK (IC50 p38α MAPK 1 = 0.45 μM and p38α 
MAPK 2 = 2.2 μM) (Peifer et al., 2007; Peifer et al., 2008), exhibited significant inhibition 
of CK1δ at 10 μM. Molecular modeling of compound 1 resulted in an optimizing strategy to 
develop (E)-3-(2,4-dimethoxy-phenyl)-N-(4-[5-(4-fluoro-phenyl)-2-methylsulfanyl-3H-
imidazol-4-yl]-pyridin-2-yl)-acrylamide (compound 17) and (E)-3-(2,4-dimethoxy-phenyl)-
N-(4-[5-(4-fluoro-phenyl)-2-methanesulfinyl-3H-imidazol-4-yl]-pyridin-2-yl)-acrylamide) 
(compound 18) as dual-specific inhibitors with high selectivity toward CK1δ at an ATP 
concentration of 100 μM (compound 17: IC50 p38α MAPK = 19 nM, IC50 CK1δ = 4 nM, 
IC50 CK1ε = 73 nM; compound 18: IC50 p38α MAPK = 41 nM, IC50 CK1δ = 5 nM, IC50 
CK1ε = 447 nM) (Peifer et al., 2009).
Recently, 3-(2,5-dimethoxyphenyl)-N-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-
yl)-pyridin-2-yl)-propanamide (compound 11b) and 4-(2,5-dimethoxyphenyl)-N-(4-(5-(4-
fluorphenyl)-2-(methylthio)-1H-imidazol-4-yl)-pyridin-2-yl)-1-methyl-1H-pyrrole-2-
carboxamide (compound 16b) have been developed with high specificity toward CK1δ 
(compound 11b: IC50 CK1δ = 4 nM, IC50 CK1ε = 25 nM, IC50 p38α MAPK = 10 nM), 16b 
(IC50 CK1δ = 8 nM, IC50 CK1ε = 81 nM, p38α MAPK = 10 nM) and remarkable efficacy 
for inhibiting the growth of various pancreatic tumor cell lines (Halekotte et al., 2017).
In order to develop a CK1δ/ε-specific inhibitor able to cross the blood-brain-barrier (BBB) 
structure-based drug design resulted in synthesis of PF-5006739 (4-{4-(4-
fluorophenyl)-1-[1-(1,2-oxazol-3-ylmethyl)piperidin-4-yl]-1H-imidazol-5-yl}pyrimidin-2-
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amine), exhibiting an IC50 value of 3.9 nM for CK1δ and 7 nM for CK1ε and showing 
centrally mediated delay of the circadian rhythm in animal models (Wager et al., 2014).
Furthermore, N-(1H-pyrazol-3-yl)-quinazolin-4-amines have been developed to specifically 
inhibit CK1δ/ε. Compounds 3c and 3d exhibited good binding interactions with CK1δ/ε and 
could therefore serve for optimizing their ability to specifically inhibit CK1δ/ε (Karthikeyan 
et al., 2017).
Finally, natural products with inhibitory activity against CK1δ/ε, like 
chloromethylhalicyclamine B, isolated from the marine sponge Acanthostrongylophora 
ingens, allow for the development of highly active CK1δ/ε-specific inhibitors, structurally 
different to the inhibitors known so far (Esposito et al., 2016).
Since SMIs often exhibit low bioavailability, off-target effects, and severe side effects, there 
are only some reports demonstrating biological activity of CK1δ-specific inhibitors in 
animal models (Table 6). Therefore, interest in identification and validation of synthetic 
peptides able to inhibit CK1δ kinase activity or to block the interaction of CK1δ with 
cellular proteins has increased remarkably.
In this context a peptide library based on the amino acid sequences of human CK1δ TV1 
and 2 was recently used to determine the dominant contacts of the interaction surface 
between α-tubulin and CK1δ. Peptide P39 (also named peptide δ−361 = peptide sequence 
starting at CK1δ amino acid 361) showed the strongest interaction with GST-α-tubulin. 
Furthermore, binding of δ−361 to α-tubulin also resulted in selective inhibition of CK1δ-
mediated phosphorylation of GST-α-tubulin, whereas phosphorylation of α-casein was not 
affected. In cells, δ−361 is able to disturb the CK1δ/α-tubulin interaction, finally leading to 
microtubule destabilization and cell death (Kruger et al., 2016).
Previously, interaction of CK1 isoforms with the DEAD-box RNA helicase DDX3X has 
been reported to result in stimulation of CK1 kinase activity and Wnt signaling (Cruciat et 
al., 2013). Moreover, Wnt-associated mutations of DDX3X can be associated with 
medulloblastoma. Using a CK1δ/ε-derived peptide library to fine-map the interaction 
domains for DDX3X on CK1δ and ε, several CK1δ- or ε-derived peptides were identified 
being able to interact with DDX3X, among them peptides δ−1, δ−41, ε−1, and ε−41. 
Furthermore, in vitro kinase reactions revealed the ability of peptides δ−1, δ−41, and ε−41 
(but not ε−1) to block the activation of CK1δ/ε by DDX3X, probably due to inhibition of 
the activating interaction of DDX3X with CK1δ/ε. Furthermore, peptides δ−1, δ−41, and ε
−41 were able to inhibit stimulation of CK1 kinase activity in cell culture. Considering that 
mutations in DDX3X identified in medulloblastoma patients increase the activity of CK1 in 
living cells, leading to aberrant stimulation of CK1-mediated pathways, such as Wnt/β-
catenin and Hh signaling, the identified interaction-blocking peptides could provide a 
powerful tool for new therapeutic therapy concepts for the treatment of Wnt/β-catenin- or 
Hh-driven cancers (Dolde et al., 2018).
Recently, a peptide microarray was also used for mapping the interaction regions within 
intrinsically disordered regions of human Axin 1, a scaffolding protein playing central roles 
in Wnt signaling. The interaction domains necessary for Axin 1 to interact with CK1δ/ε 
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were identified and it could be shown that Axin 1 and Dvl compete for CK1δ/ε-mediated 
site-specific phosphorylation thereby pointing to an important role of Axin 1 in modulating 
phosphorylation of Dvl by CK1δ/ε and activation of the canonical Wnt pathway (Harnos et 
al., 2018).
While selective inhibition of CK1δ is desired in the case of cancer or neurodegenerative 
disease, in the context of regenerative processes also activation of CK1 kinase activity could 
be of therapeutic benefit. For instance, kinase activity of CK1δ and ε has been shown to be 
essential in a model for neuronal regeneration (Bischof et al., 2011). However, no small 
molecule-based activators of CK1δ have been available so far, and while promising results 
have initially been published reporting the activation of CK1α by the small molecule 
pyrvinium (Thorne et al., 2010) a later performed study disproved the described effects. 
Instead of directly activating CK1α pyrvinium mediates its effects via a complex mechanism 
involving down-regulation of PKB/Akt and activation of GSK3 (Venerando et al., 2013).
10. Concluding remarks
Numerous studies mainly performed within the last two decades provide strong evidence 
demonstrating that CK1 isoform δ is a key player in several cellular signal transduction 
pathways. Consequently, if control mechanisms regulating expression and activity of CK1δ 
are rendered ineffective, dysregulation of CK1δ can contribute to the pathogenesis of certain 
diseases. Due to this reason numerous CK1-specific small molecule inhibitors have been 
developed in recent years. Although the development of CK1 isoform-specific inhibitors 
remains a major challenge to the scientific community, some compounds already showed 
promising results in cell culture- and animal-based studies analyzing efficacy e.g. for the 
treatment of cancer or neurodegenerative diseases.
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ABAD Aβ-binding alcohol dehydrogenase
AD Alzheimer’s disease
AIB1 amplified in breast cancer 1
AKAP A-kinase anchor protein
ALS amyotrophic lateral sclerosis
APC adenomatous polyposis coli
APC/C Cdh1 anaphase-promoting complex/cyclosome in complex with 
activator protein CDH1
ARF GAP1 ADP-ribosylation factor GTPase-activating protein
Arg or R arginine
ARNT aryl hydrocarbon receptor nuclear translocator
Asn or N asparagine
Asp or D aspartic acid
ATM ataxia telangiectasia mutated







BLAST basic local alignment search tool
BLOC-1 biogenesis of lysosome-related organelles complex-1
BMAL1 Brain and Muscle ARNT-Like 1
BYSL bystin-like protein
CAT catalytical
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CDC cell division cycle
CDK cyclin-dependent kinase
CG-NAP Golgi N-kinase anchoring protein
Chk1 checkpoint kinase 1
Chk2/Cds1 checkpoint kinase 2/replication checkpoint kinase Cds1
Ci cubitus interruptus
Ci-155 full-length cubitus interruptus
CiA cubitus interruptus positive transcription factor
CiR cubitus interruptus repressive transcription factor
CK1BP casein kinase 1 binding protein
CK1α/γ1–3/δ/ε casein kinase 1 alpha/gamma 1–3/delta/epsilon
CKL2 CDC-like kinase 2
CLL chronic lymphocytic leukemia
C-lobe C-terminal lobe
CLS centrosome localization signal
CPI-17 protein kinase C-potentiated myosin phosphatase inhibitor 
of 17 kDa
CPP conditioned place preference
CREB cyclic AMP response element-binding protein
CRY cryptochrome
CSNK1D casein kinase 1 delt
C-terminus carboxy-terminus
Cx43 connexin-43
Cys or C cysteine




DDX3X DEAD-box RNA helicase 3 X-linked
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Dma1 E3 ubiquitin-protein ligase Dma1
Dnmt1 DNA methyltransferase 1
DPC dystrophin-associated protein complex
Dpr1a dapper1a
DS Down syndrome
DUF1669 domain of unknown function 1669
Dvl dishevelled
EB1 microtubule plus-end-binding protein 1
eIF6/Tif6p49 eukaryotic initiation factor 6
Emi2 endogenous meiotic inhibitor 2
ENP1 essential nuclear protein 1
ePK eukaryotic protein kinase
ERα estrogen receptor α
FAM83 family with sequence similarity 83
FASPS familial advanced sleep phase syndrome
FoxG1 forkhead box G1





Gly or G glycine
GSK3β glycogen synthase kinase 3β
GST glutathione S-transferase
GVBs granulovacuolar degeneration bodys
Hh hedgehog
HIF-1α hypoxiainducible factor 1α
hnRNP A1 heterogeneous nuclear ribo-nucleoprotein A1
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HPI hydrophobic pocket I
HRII hydrophobic region II
Hsp90/70 heat shock protein 90/70
HTP high-throughput
Huwe1 E3 ubiquitin-protein ligase Huwe1
IC50 half maximal inhibitory concentration
ICP0 human herpes virus (HHV) E3 ubiquitin ligase
IFNAR1 interferon alpha/beta receptor 1
Ihh Indian hedgehog
IKK inhibitor of κB (IκB) kinase
Ile or I isoleucine
ISC intestinal stem cell
IWP inhibitor of Wnt production
kcat catalyst rate constant
KD kinase domain
KHD kinesin homology domain
Km Michaelis constant
LATS1/2 large tumor suppressor kinase 1/2
LEF-1 lymphocyte enhancer factor-1
Leu or L leucine
LRP lipoprotein receptor-related protein
LTP low-throughput
Lys or K lysine
M molar
m6A N6-methylation
Mam1 Monopolin complex subunit Mam1
MAP microtubule-associated protein
MAPK mitogen activated protein kinase
MAPT microtubule-associated protein tau
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MBP myelin basic protein
MBP myelin basic protein
MDM2 murine double minute 2 homolog
MEF mouse embryonic fibroblast
Met or M methionine
MESA mature-parasite-infected erythrocyte surface antigen
mGluR group I metabotropic glutamate receptor
MST1/2 mammal sterile-20 like kinase 1/2
mTNFα transmembrane tumor necrosis factor α
MTOC microtubule-organizing center
MTSS1 metastasis suppressor 1
NEDD4 neural precursor cell expressed developmentally down-
regulated protein 4
NFAT1 nuclear factor of activated T-cells 1
NFTs neurofibrillary tangles
N-lobe N-terminal lobe
NLS nuclear localization signal
nm23-H1 nucleoside diphosphate kinase A
Nop56 nucleolar protein 56
NPs neuritic plaques
N-terminus amino-terminus
p53 tumor protein 53
P-bodies processing bodies
PCP planar cell polarity
PD Parkinson’s disease
PDB protein data bank
PDC parkinsonism dementia complex of Guam
PET positron emission tomography
PER period circadian protein homolog
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PGC-1α proliferator-activated receptor γ co-activator 1α
Phe or F phenylalanine
PiD Pick’s disease
PKA protein kinase A
PKB/Akt protein kinase B
PKCa protein kinase C alpha
PKD2 protein kinase D2
Plk1 polo-like kinase 1
Porcn porcupine
PP1 protein phosphatase 1
PPND pallido-ponto-nigral degeneration
ppUL44 human cytomegalovirus phosphoprotein
Pro or P proline
PS-2 presenilin-2
pSer phospho-serine
PSP progressive supranuclear palsy
Ptch patched
pThr phospho-threonine
RanBPM Ran-binding protein in the microtubule-organizing center 
(MTOC)
RBC red blood cell
Rec11 meiotic recombination protein Rec11
Rec8 meiotic recombination protein Rec8
REGγ 11S regulatory particles, 28-kDa proteasome activator γ
RhoA Ras homolog family member A
RPL4/8/13 ribosomal protein L4/8/13
SCF skp cullin F-box containing complex
SCS sulfatide and cholesterol-3-sulfate
Ser or S serine
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Shh sonic Hedgehog (Shh)
Sid4 septation initiation protein sid4
Sid4 septation initiation protein Sid4
SMAD SMA/mothers against decapentaplegic
SMI small molecule inhibitor
Smo smoothened
SNAP25 synaptosomal nerve-associated protein 25
SPBs spindle pole bodies
SPRY2 sprouty2
Sre1N yeast sterol regulatory element-binding protein homolog
SRR-1 sensitivity to red light reduced 1
STAG3 stromal antigen 3
SV2A synaptic vesicle protein 2A
SV40 T-Ag simian virus 40 large T-antigen
SV40 simian virus 40
Swi6 chromatin-associated protein swi6
TAZ tafazzin
TDP-43 TAR DNA-binding protein of 43 kDa
TEAD TEA domain
TGN trans Golgi network
Thr or T threonine
TOP2A topoisomerase IIα
TOPOII-α topoisomerase II α
TPA 12-O-tetradecanoylphorbol-13-acetate
TV transcription variant
Tyr or Y tyrosine
UHRF1 ubiquitin-like containing PHD and RING finger domains 1 
protein
UVB ultraviolet B radiation
Xu et al. Page 37














Vangl2 planar cell polarity protein Van Gogh-like 2
Vmax maximum enzyme reaction velocity
Wee1 Wee1 G2 checkpoint kinase
Wnt Wingless/Int-1
X any amino acid
Y any amino acid except serine or threonine
YAP yes-associated protein
β-TrCP beta-transducin repeat containing protein
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Comparison of the amino acid sequences of three different CK1δ sequences in human, rat, 
and mouse. The alignment presented in (A) is followed by a display of the conserved 
regions, the quality, the consensus sequence as well as the occupancy of the alignment. The 
conservation as well as the quality is displayed with a color code ranging from yellow 
(highly conserved, good quality) to brown (poorly conserved, poor quality) (B). Alignments 
presented in panels A and B are shown starting from amino acid 372. The sequences are also 
displayed in a phylogenetic tree, indicating the relationship between the various CK1δ 
variants. The alignments as well as the phylogenic tree were generated using the alignment 
information from the Clustal Omega algorithm (Madeira et al., 2019) (C). TV, transcription 
variant.
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Exon structure of the three transcription variants of CK1δ in humans. The stop codon 
position of each variant is marked with the asterisk. The information of TV1, TV2, and TV3 
can be found using the data bank NCBI (GI: 13097702, 16041786, and 1393428169). Bp, 
base pairs; TV transcription variant.
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Predicted RNA folding structure of the polyadenylation motif and the flanking regions of 
TV1 and TV2 on exon 10 (A) as well as TV3 on exon 11 (B). The minimum free energy 
values for TV1/TV2 and TV3 are −28.70 kcal/mol and −16.03 kcal/mol, respectively. This 
might indicate that TV1 and TV2 are less polyadenylated compared to TV3 based on the 
observation that stable secondary structures decrease the polyadenylation of the specific site 
(Klasens et al., 1998).
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Three-dimensional structure of human CK1δ. Representation of the three-dimensional 
structure of human CK1δ. The structure of the N-lobe mainly consists of β-sheet strands 
while the larger C-terminal lobe is mainly composed by α-helices and loop structures. 
Structural elements are labeled according to Xu et al. (1995). Domains and residues of 
functional importance are labeled accordingly. Within loop L-89 the DFG motif is located 
with its aspartate residue being crucial for kinase activity and enzymatic function. 
Identification of a tungstate binding domain, indicated by W1, led to the identification of a 
recognition motif for the binding of phosphorylated substrates. The position of the catalytic 
loop (L-67) is marked with the asterisk (Xu et al., 1995; Longenecker et al., 1996). The 
figure was created by using CK1δ crystallization data deposited in the protein data bank 
(PDB) with ID 6GZM (Minzel et al., 2018).
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Detailed representation of secondary structure, functional domains, and functional amino 
acid residues in the kinase domain of human CK1δ. Localization of structural elements 
building the CK1δ kinase domain is shown for α-helices, β-sheets, turns, and loop-
structures. Nomenclature of elements is indicated as first published by Xu et al. (1995). 
Structures not described in the initial publication are shown in grey. Domains of functional 
importance are marked with red boxes while amino acid residues involved in ATP binding or 
substrate recognition are marked with yellow or green background, respectively. Because 
human CK1δ TV1, 2, and 3 are fully conserved in the N-terminal domain and the kinase 
domain, the depicted protein sequence is representative for all three variants. Unfortunately, 
data regarding three-dimensional structure of the C-terminal domain is not available. CLS, 
centrosome localization signal; KHD, kinesin homology domain; NLS, nuclear localization 
signal; TV, transcription variant.
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Posttranslational modification of human CK1δ. Identified posttranslational modifications of 
CK1δ TV1 are indicated at their reported positions. Because most modifications have been 
reported for the C-terminal domain, this domain is depictured in a stretched presentation 
compared to the kinase domain. In the case of phosphorylation the distinction is made 
between reports of low-throughput studies and high-throughput studies. The figure was 
created based on information provided for CK1δ by PhosphoSitePlus® (Hornbeck et al., 
2015). HTP, high-throughput studies, LTP, low-throughput studies, TV, transcription variant.
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The three transcription variants of CK1δ show significant differences in their kinetic 
parameters and their (auto-)phosphorylation status. Catalytical (CAT) enzyme activity 
[nmol/min/mg] was used as readout after having performed in vitro kinase reactions using 
radioactively labeled ATP to identify the amount of phosphorylated α-casein (A) and β-
catenin (GST-β-catenin1–181) (B) of the three identified CK1δ TVs. Statistically significant 
differences between the whole curves of the TVs were tested by a Kruskal-Wallis test using 
an uncorrected Fisher’s LSD test as follow-up. * indicates p ≤ 0.05, ** indicates p ≤ 0.01, 
and *** indicates p < 0.001. (C) Analysis of the phosphorylation status of the different 
CK1δ transcription variants after autophosphorylation by two dimensional phosphopeptide 
analysis. The phosphopeptide analysis of TV3 clearly shows differences in major and minor 
phosphopeptides compared to the phosphopeptide maps of TV1 and TV2. Phosphopeptides 
A-E are present in all three CK1δ transcription variants, whereas phosphopeptides L, K, J, 
and M were only observed for TV1. Phosphopeptides O and N are only present in TV3. 
Figure panels in (C) showing phosphopeptide maps of CK1δ TV1 and TV2 are a derivative 
of “Fig. 2” published in Bischof et al. (2012), used under CC BY 4.0 (http://
creativecommons.org/licenses/by/4.0/). CAT, catalytical; TV, transcription variant.
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Expression trend frequency of different cancer types. Frequencies of patients following each 
expression trend for CK1δ are presented for all relevant cancer types. For each patient, log2 
fold-change (log2FC) values greater than zero were considered to follow an over-expression 
trend, less than zero to follow an under-expression trend. Patients with log2FC = 0 were 
excluded from the dataset. Note that all patients are included in this graphic, irrespective of 
statistical significance of the trend. Data is based on the BioXpress online tool (Wan et al., 
2015; Dingerdissen et al., 2018).
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Table 2
Km [μg] and Vmax [nmol/min/mg] of CK1δ TV1, TV2, and TV3 using α-casein as well as β-catenin as 
substrates. Values were calculated using a non-linear Michaelis-Menten fit. Km, Michaelis constant; TV, 
transcription variant; Vmax, maximum enzyme reaction velocity.
CK1δ variant α-Casein β-Catenin
Km [μg] Vmax [nmol/min/mg] Km [μg] Vmax [nmol/min/mg]
TV1 15.54 236.02 0.8121 3.63
TV2 17.21 548.88 0.2527 2.37
TV3 24.86 576.60 0.3885 7.33
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Table 3
CK1δ-specific substrates. Substrates reported for CK1δ-targeted phosphorylation (in vitro and in vivo) are 
listed and grouped according to their associated functions. Only substrates reported for human CK1δ or 
appropriate orthologous proteins (e.g. in yeast species) are included.
Substrates References
Cancer-associated proteins:
 – Adenomatous polyposis coli (APC) (Gao et al., 2002)
 – Axin (Gao et al., 2002)
 – β-Catenin (Amit et al., 2002)
 – Full-length cubitus interruptus (Ci-155) (Price and Kalderon, 2002)
 – Dishevelled (Dvl) (Gao et al., 2002)
 – Nucleoside diphosphate kinase A (nm23-H1) (Garzia et al., 2008)
 – Dapper1a (Dpr1a) (Teran et al., 2009)
 – Fat (Sopko et al., 2009)
 – Deoxycytidine kinase (dCK) (Smal et al., 2010)
 – Yes-associated protein (YAP) (Zhao et al., 2010)
 – Metastasis suppressor 1 (MTSS1) (Zhong et al., 2013)
 – Neural precursor cell expressed developmentally down-regulated protein 4 (NEDD4) (Liu et al., 2014)
 – Sprouty2 (SPRY2) (Yim et al., 2014)
Control of mitotic or meiotic processes:
 – Meiotic recombination protein Rec8 (Rec8) (Ishiguro et al., 2010)
 – Endogenous meiotic inhibitor 2 (Emi2) (Isoda et al., 2011)
 – Wee1 (Penas et al., 2014)
Cytoskeleton-associated and scaffolding proteins:
 – Annexin II/lipocortin II (Gao et al., 2000)
 – Desmoglein 2 (Gao et al., 2000)
 – Keratin 17 (Gao et al., 2000)
 – Microtubule-associated protein 1A (MAP1A) (Wolff et al., 2005)
 – Microtubule-associated protein 4 (MAP4) (Behrend et al., 2000b)
 – Stathmin (Behrend et al., 2000b)
 – Tau (Behrend et al., 2000b)
 – α/β-Tubulin (Behrend et al., 2000b)
 – γ-Tubulin (Behrend et al., 2000b)
 – Connexin-43 (Cx43) (Cooper and Lampe, 2002)
 – Ras homolog family members A and B (Kawakami et al., 2008)
 – End-binding 1 (EB1) (Zyss et al., 2011)
 – Sid4 (Johnson et al., 2013)
 – Ran-binding protein in the microtubule-organizing center (RanBPM) (Wolff et al., 2015)
DNA-/RNA-associated proteins:
 – Chromatin-associated protein swi6 (Swi6) (Ho et al., 1997)
 – Heterogeneous nuclear ribo-nucleoprotein A1 (hnRNP A1) (Gao et al., 2000)
 – Putative RNA helicase (Gao et al., 2000)
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Substrates References
 – Nuclear factor of activated T cells 1, 2, and 4 (NFAT1, 2, 4) (Okamura et al., 2004)
 – Forkhead box G1 (FoxG1) (Regad et al., 2007)
 – Topoisomerase Iiα (TOP2A) (Grozav et al., 2009)
 – DNA methyltransferase 1 (Dnmt1) (Sugiyama et al., 2010)
 – Ubiquitin-like containing PHD and RING finger domains 1 protein (UHRF1) (Chen et al., 2013)
 – Yeast sterol regulatory element-binding protein homolog (Sre1N) (Brookheart et al., 2014)
Golgi- and vesicle-associated proteins:
 – ADP-ribosylation factor GTPase-activating protein (ARF GAP1) (Yu and Roth, 2002)
 – Snapin (Wolff et al., 2006)
 – Protein kinase D2 (PKD2) (von Blume et al., 2007)
 – Synaptic vesicle protein 2A (SV2A) (Zhang et al., 2015a)
Mediators of cellular stress:
 – Tumor protein 53 (p53) (Knippschild et al., 1997)
 – Murine double minute 2 homolog (Mdm2) (Winter et al., 2004)
 – Hypoxia-inducible factor 1α (HIF-1α) (Kalousi et al., 2010)
Proteins associated to neurodegenerative processes:
 – Presenilin-2 (PS-2) (Walter et al., 1998)
 – Cyclin-dependent kinase 5 (CDK5) (Sharma et al., 1999)
 – α-Synuclein (Okochi et al., 2000)
 – β-Secretase (BACE1) (Walter, Fluhrer et al. 2001)
 – Parkin (Yamamoto et al., 2005)
 – Cyclic AMP response element-binding protein (CREB) (Shanware et al., 2007)
 – Myelin basic protein (MBP) (Kawakami et al., 2008)
 – TAR DNA-binding protein of 43 kDa (TDP-43) (Nonaka et al., 2016)
Receptors and receptor-associated proteins:
 – Transmembrane tumor necrosis factor α (mTNFα) (Watts et al., 1999)
 – Amplified in breast cancer 1 (AIB1) (Giamas et al., 2009)
 – Estrogen receptor α (Erα) (Giamas et al., 2009)
 – Adiponectin (Xu et al., 2015)
Regulation of circadian rhythm:
 – Period circadian protein homolog 1–2 (Camacho et al., 2001)
 – Cryptochromes 1 (CRY1) and 2 (CRY2) (Walton et al., 2009)
 – Proliferator-activated receptor γ co-activator 1α (PGC-1α) (Li et al., 2011b)
Ribosome-related proteins:
 – Nucleolar protein 56 (Nop56) (Gao et al., 2000)
 – Ribosomal proteins L4 (RPL4), L8 (RPL8), L13 (RPL13) (Gao et al., 2000)
 – Eukaryotic initiation factor 6 (eIF6)/Tif6p49 (Biswas et al., 2011)
 – Essential nuclear protein 1 (ENP1)/bystin-like protein (BYSL) (Zemp et al., 2014)
 – LTV1 (Zemp et al., 2014)
Viral proteins:
 – Human cytomegalovirus phosphoprotein (ppUL44) (Alvisi et al., 2011)
 – Human herpes virus (HHV) E3 ubiquitin ligase (ICP0) (Chaurushiya et al., 2012)
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Substrates References
 – Simian virus 40 large T-antigen (SV40 T-Ag) (Hirner et al., 2012)
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